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BMI: body mass index 
CAP: College of American Pathologists 
CD: Crohn’s disease 
CD: cluster differentiation 
CDIF: Clostridium difficile infection 
CLA: conjugated lineolic acid 
CLAI: Clinical Laboratory Improvement Amendment 
CXCR: C-X-C motif ligand chemokine receptor 
D: donor 
DAB: diaminobenzidine tetrahydrochloride 
DCs: dendritic cells 
DSS: dextran sulfate sodium 
Dx: diagnosis 
E: ethnicity 
EIA: enzyme immunoassay 
F: female 
FFAR2: free fatty acid receptor 2 
FMT: fecal microbiota transplantation 
FOS: fructooligosaccharides 
G: gender 
GABA: gamma-aminobutyric acid 





GIT: gastrointestinal tract 
GLP: Good Laboratory Practice 
GOS: galactooligosaccharides 
GPR43: G-protein coupled receptor 43 
H: Hispanic 
HC: high cellulose (12.5% cellulose) 
HE: hematoxylin-eosin 
HF (or ω6): high fat (ω6) diet (40% caloric content corn oil/linoleic acid) 
HMP: Human Microbiome Project 
IBD: inflammatory bowel disease 




IND: Investigational New Drug 
IRB: Institutional Review Board 
LC: low cellulose (2.5% cellulose)  
M: male 
MGB axis: microbiota-gut-brain axis 
MLNs: mesenteric lymph nodes 
NEC: necrotizing enterocolitis 
NF-κB: nuclear factor kappa-light chain enhancer of activated B cells 
NH: non-Hispanic 
NIH: National Institute of Health 
OTUs: operational taxonomic units 
P21/30/80/90/120, 30/80/90/120 days postnatal age 
PBL: peripheral blood 
PBMCs: peripheral blood mononuclear cells  
PBS: phosphate-buffered solution 
PCoA: principal coordinate analysis 
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PCR: polymerase chain reaction 
PRED: prednisone 
PSA: polysaccharide A 
Pt: patient 
qMRI: quantitative magnetic resonance imaging 
R: race 
R10 and R40: 10 or 40 days of reversal following high cellulose/ high ω6 diet 
SCFAs: short chain fatty acids 
SOPs: Standard Operating Procedures 
TCMC: Texas Children’s Microbiome Center 
TNF-α: tumor necrosis factor α 
Tx: therapy 






1.1 Nutritional developmental origins of disease hypothesis 
There is a critical developmental period when nutrition may modify the 
predisposition to diseases later in life.  The hypothesis “Developmental Origins of Health 
and Diseases” was established in the late 80’s by Barker.(1) The retrospective studies 
showed that infant mortality (undernutrition in utero and low birth weight) permanently 
changes body metabolism and leads to an increased cardiovascular and metabolic disease 
risk later in life. The possible mechanism behind the hypothesis is programming. This 
process describes the mechanism whereby stimuli at a critical period of development may 
have long-lasting and irreversible effect on the body structure or function.  
 
1.2 What biologic systems can be modulated by the nutrition? 
Biological systems are most likely to respond to environmental stimuli when they are 
in flux. Developmental maturation and modification is a window opportunity to alter the 
biological systems. By definition, the biological system has to be responsive for 
environmental factors and nutritional stimuli. The biological system has to stay stable once 
adjusted to external stimuli. The biological system needs to be penetrant, and convey 
phenotype effects. 
 
In my studies, we focused on the MICROBIOME, and how such a biological 
system may be modulated by the nutrition and to characterize the effect on host by 
these alterations.  
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1.3 The Human Microbiome Project 
The Human Microbiome Project (2) was established in 2008 as a five-year project 
with a total budget of $115 million funded by the National Institute of Health (3) to 
characterize the human bacteria composition associated with health and disease.  
The human microbiome is a pool of all microorganisms living in association with 
our body. The microorganisms contain ecological communities of commensal, symbiotic 
and pathogenic organisms. The number of bacteria is ten times more than the number of 
human cells; and the compounded genes are thousand times more in the bacteria than 
presented in the human genome. 
An individual’s microbiome is varying depending on genetic predisposition, the 
mode of delivery (natural birth or cesarean section), age and different environmental factors 
such as dietary and nutritional intake, physical activity, use of different drugs, and lifestyle. 
The homeostasis of gut microbiome is an important key to balance health. On the other 
hand, dysbiosis (alteration of abundance in bacterial taxa compared to healthy individuals) 
is associated with diseases and could lead to different disorders. Gut bacteria have a 
tremendous number of roles, including (1) modifying energy balance and metabolism, and 
(2) controlling pathogen colonization and resistance.  The bacteria performing these roles – 
and the mechanisms they use – are actively being uncovered.   
The improving diagnostic technique took over the culture-based procedures and 
provided comprehensive characterization of the microbial community. The advanced high-
throughput technologies have changed the global view on microbiome dramatically. 
Metagenomics is the study of genetic materials recovered directly from environmental 
samples. 
The process starts with the extraction of DNA by the biological sample, followed by 
amplification and sequencing of 16S ribosomal RNA genes. The 16S rRNA gene allows 
taxonomic identification from species to phyla level. The identification is made by the 
comparison to a reference-based library. The advanced bioinformatics techniques provided 
unique opportunity to map the microbial community and give microbial information about 
biological samples. Adding metabolic networks linked to the microbiome provides more 
information on function and offers functional profile. 
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Focusing on the intestinal microbiome, one large step forward came with the 
completion of the HMP. Being catalogued the different bacteria species from stools of 242 
healthy individuals.(4; 5)  The HMP has taught us that the gastrointestinal (GI) microbiome 
contains around 15,000 to 36,000 bacterial species, and specifically enriched in 
Bacteroidetes and Firmicutes. These two phyla cover nearly 90% of bacteria in the human 
gut microbiome. Proteobacteria, Actinobacteria, Fusobacteria and Verrucomicrobia are also 
presented in the human gut microbiome. However, there is a highly remarkable diversity 
between individuals at a lower level of taxonomy such as species or strain.  
 
1.4 The microbiome matures during pediatric development 
The GI microbiome changes during development.  In the beginning, the fetal GI 
tract (6) is sterile. Colonization of the GIT begins immediately at birth and is directly 
influenced by mode of delivery, with infants delivered by Cesarean section having delayed 
colonization and decreased colonization with Bacteroides fragilis as well as Lactobacillus- 
and Bifidobacterium-like bacteria.(7) Controversial studies showed that the placenta 
harbors a unique microbiome.(8) First-pass meconium samples of newborns show 
extremely limited relative abundance of bacteria.(9; 10) The gut is rapidly colonized 
thereafter. After the first week of life, the microbiome appears to stabilize but varies 
depending on how the infant is fed.  Breast-fed infants are colonized mostly by 
Bifidobacteria and Ruminococci, and lesser quantities of facultative anaerobes (such as 
Streptococci, Staphylococci, Enterococci, Lactobacilli and Enterobacteria).(11; 12) 
Formula-fed infants are colonized by a larger proportion of Firmicutes, Bacteroides and 
Proteobacteria. Recent studies have shown that formulas supplemented with prebiotics can 
increase the amount of Bifidobacteria and Lactobacilli in formula fed infants to similar 
levels found in breast-fed newborns.(13) In infancy, the microbiome continues to change, 
but by age 2 or 3, an “adult-like” microflora is established. However, a recent study from 
our collaborators provided evidence that healthy children and adult microbiome remarkably 
differs in composition and function.(14) Adult microbiome contains more Bacteroides 
species, while the relative abundance of Bifidobacterium species, Faecalibacterium species 
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and Lachnospiraceae are increased in children. This study proposes that microbiome may 
undergo a more prolonged development and more responsible for environmental effects. 
  
1.5 The microbiome is nutritionally responsive  
Is it really true that ‘We are what we eat’?  From a gut microbiome perspective, what 
we eat does indeed determine what bacteria we have more so than nationality, age, gender 
or body mass index (BMI) (Table 1).  Humans can generally be divided into three 
‘enterotypes’ based on the genera of bacteria in their gut.(15)  
 
Table 1 Nutrition-associated modifications of the microbiota composition. 
Dietary habits Microbiota alteration 
‘Western' diet (animal protein, saturated fat)  Bacteroides enterotype 
Polyunsaturated fat and alcohol Ruminococcus enterotype 
High carbohydrate diet Prevotella enterotype 
Ancient rural communities (high carbohydrates, plants) ↑Bacteroidetes (Prevotella) 
Vegetarian lifestyle ↓Bacteroides, Escherichia 
High fiber ↑Bacteroidetes, Actinobacteria 
  ↓Firmicutes, Proteobacteria 
High fat ↑Firmicutes, Proteobacteria 
  ↓Bacteroidetes 
High carbohydrate  ↑Firmicutes 
  ↓Bacteroidetes 
 
Humans consuming more modern diet riches in animal protein and saturated fat – the 
“Western diet” – harbor the Bacteroides enterotype. In contrast, those who consume high 
amounts of carbohydrates, similar to those from ancient rural communities, have the 
Prevotella enterotype. Finally, those with high polyunsaturated fat and alcohol intake 
belong to the Ruminococcus-dominated enterotype.  The functional capacity of the human 
gut microbiome can be mapped to the enterotypes. For instance, the Bacteroides enterotype 
is characterized by genes involved in biotin, riboflavin, panthothenate and ascorbate 
biosynthesis were enriched in the Bacteriodes enterotype, associated with genes encoding 
enzymes involved in the degradation and fermentation of these nutrients. The Prevotella 
enterotype is enriched in thiamine and folate biosynthesis genes, while the Ruminococcus 




1.6 The human microbiome as an active metabolizer 
Gut microbiota are not passive responders to their host’s diet; rather they metabolize 
a number of substances and function as a nutritive source for the host.  For example, 
bacteria ferment complex carbohydrates into short chain fatty acids (SCFAs).  SCFAs in 
turn boost the human metabolism level; increase energy intake and the bioavailability of 
toxins.  Increased SCFAs decrease colonic pH, inhibit the growth of pathogens, and these 
nutritional components are the main energy source of colonic epithelial cells. All three 
SCFAs are reported to enhance colonic blood flow, to stimulate the proliferation of normal 
crypt cells. By increasing the frequency of the smooth muscle contractions of the colonic 
mucosa, acetate and propionate leads to an enhanced colonic motility.  Butyrate is the main 
source (about 60 to 70%) of energy for the colonic epithelial cells. Butyrate also influences 
cell growth and differentiation.  Propionate is associated with lipid metabolism 
  Additionally, pharmaceutical industries are exploiting the nutritive role of SCFAs, 
and provide prebiotics. Prebiotics are nonviable nutritional components that modify the 
colonic microbiota conferring benefits for the host health. These components escape 
digestion in the upper GIT and reach the colon, where they are fermented by the gut 
microbiota. Inulin-derived fructooligosaccharides (16) and galactooligosaccharides (GOS) 
change the composition and activation of the microbiota, especially lead to an increase in 
the amount of Bifidobacteria and Lactobacilli. These products have significant health 
benefits, including the influence of laxation, mineral absorption, lipid metabolism, and 
potential anticancer and anti-inflammatory effects.   
Microbes also generate a number of essential vitamins for the host. For example, 
Bacteroides fragilis is known to produce Vitamin K2, therefore a key component in bone 
and vascular health (increases bone mineral density and modulate the blood coagulation). 
Another nutrient, Vitamin B12 (cobalamin) is produced by Lactobacillus reiteri, and 
important for growth and the development of the nervous system. The absence of this 
bacteria and its product decreases the risk of different neurological and hematological 
disorders. Other micronutrients, such as biotin, folate, thiamin, riboflavin and pyridoxine 
(produced by Bifidobacterium), are not only reinforcing the immune system, but also have 
epigenetic effects to regulate cell proliferation. Choline metabolites are related to 
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Faecalibacterium prausnitzii and Bifidobacterium, and linked to glucose and lipid 
homeostasis, involved in obesity, diabetes and cardiovascular diseases. 
Malnutrition and obesity exemplify the relationship between the gut microbiota and human 
nutrition.(17; 18) Undernutrition (kwashiorkor or marasmus) is linked to an altered 
microbiota with overall reduced gene content. Malnourished children had increased in 
Lactobacillus and Bifidobacterium species and decreased in Bacteriodales with nutritional 
therapy.  They also showed signs of a more robust microbiome, including stools with 
reduced saccharides and an increase of carbohydrate, amino acid, nucleotide and fatty acid 
metabolism products. .  Additionally, antibiotic supplemented therapeutic food can increase 
the percentage of weight gain and decrease the mortality than therapeutic food only.(19) 
According to the randomized, double-blinded, placebo-controlled trial, the recovery rate of 
severe acute malnutrition was 88.7% in the amoxicillin-complemented group and 90.9% in 
the cefdinir-complemented group, while placebo control reached only an 85.1% recovery 
rate. The mortality rate changed respectively (4.8% in the amoxicillin group, 4.1% in the 
cefdinir group and an increased 7.4% in the placebo group).   
The obesity-associated microbiota changes are better characterized. Obese individuals have 
a significantly less diverse microbiome compared to non-obese controls.  They are 
dominated by Actinobacteria (75%) and Firmicutes (25%) phyla, compared to 
Bacteroidetes (40%) in controls.   
 
1.7 Rapid microbiome responses to marked diet changes 
Changes in diet may lead to alteration in gut enterotypes.  For instance, individuals 
switching from the Western diet to a vegetarian lifestyle showed decreased amount of 
Bacteroides and the related genus Escherichia.  These changes in turn influence overall 
bowel health.  Increased endotoxin linked to Bacteroides and Escherichia increases 
systemic inflammation, whereas high-fiber diets promoting Prevotella correlate with 
increased bowel transit and production of SCFAs that stimulate intestinal cells. 
Supporting the central role of diet in shaping the microbiome, radical dietary change alters 
the microbiota composition. Wu and his research group showed that switching from a high 
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fat/low fiber diet to a high fiber/low fat diet led to detectable changes within 24 hours.(20) 
Both the composition of bacteria and bacterial gene expression patterns changed, indicating 
an acute shift in how the microbiome metabolized nutrients. However, only long-term diet 
changes may lead to actual switches among the three enterotypes.   
 
1.8 The microbiome possesses compositional stability  
The species composition may be highly variable among different people.  However, 
within the same person, the gut microbiome composition varies little over time compared to 
other body sites such as oral cavity, skin and hair.(21)  
 
1.9 The microbiome possesses metabolic stability 
The second core principle is that even though microbial taxa may vary among 
individuals, the metabolic pathways catalyzed by the bacteria remain stable.(5) Hence, 
current techniques focused on identifying specific bacteria, such as shotgun sequencing of 
bacterial genomic DNA, may misrepresent the actual metabolic capacity of a microbiome. 
Instead, much larger scale systems biological approaches are needed in the future to 
confirm the conclusions of the Human Microbiome Project Consortium in respect to the 
high similarity in metabolic patterns representative of different microbial habitats of the 
human body. 
 
1.10 The dynamically changing microbiota throughout life stages 
The gut microbiome loses richness with age, correlating with altered dietary habits, 
chronic illnesses, and increased use of medications.(22) 
 
1.11 The role of host immunity and infections in the modulation of gut microbiota 
Gut microbes must maintain the barrier between host and all the environmental 
challenges present in the intestine. Stratification and compartmentalization is occurred to 
decrease the exposure of external stimuli and increase the efficacy of the immunity.(23) 
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The microbiota actively interacts with the innate and adaptive immune system. The infant 
gut microbiome affects the maturation of the host immune system and carefully adjust it in 
early days of life. The microbiota contributes to develop the gut-associated lymphoid 
tissues (GALTs). The GALTs are immune structures, which participate in lymphocyte 
functions and have an important role in tolerance or inflammation. The main function of the 
microbiota-induced development of the intestinal immune system is the promoted T helper 
17 and T helper 1 cells (activated by the lamina propria dendritic cells [DCs] and 
macrophages) and the stimulated intestinal epithelial cells and DCs promoting IgA-
producing B cells and plasma cell differentiation. (24; 25) 
The decision-making process of the immune system (recognition of pathogenic or 
non-pathogenic bacteria) is orchestrated by the host-microbial interaction. The pathogenic 
bacteria will be destructed and eliminated, while the host intestine will tolerate the 
beneficial bacteria. The finely balanced interplay between the healthy beneficial microbiota 
and the exogenous and potentially harmful pathogens maintains the intestine homeostasis. 
This process is based on metabolites cellular and soluble elements associated to the 
microbiota and sensed by the immune system. These metabolites can be uniquely produced 
by the microbes (such as SCFAs), or evaluated (e.g. retinoic acid), or metabolized by the 
microbes (such as the host-presented bile acids).(18; 26) These specific metabolites and 
their activities -can present the current microbial composition and host-microbial 
communication. 
Microbiota can produce nutritional components -short chain fatty acids (SCFAs), 
conjugated lineolic acid (CLA), polysaccharide A (PSA) gamma-aminobutyric acid 
(GABA) and histamine- which affect the host immune system via direct or indirect 
mechanisms. As an immunological standpoint, the end products of carbohydrate 
fermentation (by SCFAs) can bind to a G-protein coupled receptor 43 (GPR43) or free fatty 
acid receptor 2 (FFAR2); and affect inflammatory responses. (27) The receptor-binding 
mechanism leads to an over-expression of interleukin (IL)-10, and a decreased expression 
of IL-12 in the human monocytes. This interaction is a great example for the diet-GI 
bacterial metabolism –immune and inflammatory response complex. Furthermore, SCFAs 
play a role in the proliferation-occurred apoptosis of activated neutrophils via the decreased 
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tumor necrosis factor α (TNF-α), IL-8 and inhibited nuclear factor kappa-light chain 
enhancer of activated B cells (NF-κB) pathway leading to an enhanced anti-inflammatory 
response. 
Microbiota can also generate CLA, which are produced mostly by Bifidobacterium 
breve, B. longum, Lactobacillus and Propionibacterium and modulate the immune system 
with its anti-inflammatory properties. PSA (produced by Bacteroides fragilis) is also 
characterized by its immunomodulatory and anti-inflammatory activities. The 
neurotransmitters (GABA and histamine) affect the central nervous system produced by 
various microorganisms, especially Lactobacillus brevis.(28) 
 
1.12 Postnatal (29) nutritional exposures affect intestinal inflammation and associate 
with IBD susceptibility 
Inflammatory bowel diseases (IBDs) including Crohn’s disease (CD) and ulcerative 
colitis (UC), have been recognized as disorders whereby environmentally sensitive 
developmental factors may play an important etiologic role (30). The peak incidence of 
IBD is in young adulthood. Therefore, there is a prolonged developmental period from 
conception to young adulthood for environmental influences to critically impact biological 
systems relevant for IBD pathogenesis (31). Important elements of IBD pathology are 
thought to be the intestinal microbiome, the gut mucosa, and the mucosa associated 
immune system (30; 32). Our research group recently shown in a mouse model that 
maternal supplementation of 4 micronutrients could significantly modify offspring colitis 
susceptibility in association with colonic mucosal gene expression and microbiome 
alterations (33; 34). However, the same diet did not induce obvious phenotype changes 
with respect to intestinal inflammation when given during pediatric development. These 
findings underscored that pertinent nutritional factors can exert persistent colitis modifying 




1.13 Cellulose supplementation early in life ameliorates acute colitis in adult mice 
As for IBD, the decreased consumption of dietary fibers has been recognized to 
potentially play an etiologic role (35). The rising incidence of IBD in the developed world 
associating with a decrease in dietary fiber intake was emphasized by Burkitt during the 
early 70’s (36). In agreement with this observation, a recent study highlighted the 
importance of different nutritional habits and gut microbial diversity in children from two 
different continents and cultures (European and a rural African village) (37). The authors 
called the attention to the reduction of fiber intake and the associated decrease of microbial 
richness in European children, which may be relevant in respect to gastrointestinal diseases. 
Indirect epidemiologic data supports these conclusions where high fiber and fruit 
consumption are associated with a decreased risk of CD and high vegetable intake is 
associated with a decreased risk of UC (35).  
Cellulose is an insoluble fiber and an abundant component of a vegetarian diet since 
it is present in most plant tissues (38). It has a proliferative effect on the colon, mostly in 
the distal areas in rodent models (39). The colonic trophic effects of cellulose do not 
depend on microbial fermentation (40), as opposed to the case of other fibers, such as guar 
gum (41). Although cellulose may be fermented in the colon, the secondary production of 
SCFAs is limited (42). Despite the limited fermentation of cellulose, it has been shown to 
substantially modify colonic microbial composition (43). These results implicate it as a 
potential prebiotic (non-digestible carbohydrate that favors the growth of desirable 
microflora in the large bowel). Since cellulose is a major component of vegetable and fruit 
fibers, the indirect nutritional epidemiologic data already discussed (35; 37) would support 
it as an important factor in IBD pathogenesis.  However, the effect of cellulose on 
mammalian colonic mucosal microbiome (which may be more relevant for IBD 
pathogenesis than luminal bacteria (44; 45)), or colitis susceptibility has not yet been 
investigated especially from the developmental origins perspective.  
Therefore, in this study, we examined the direct and prolonged effects of pediatric 
cellulose supplementation on large intestinal growth, chemically induced colitis 




1.14 Loss of omega-6 fatty acid induced pediatric obesity protects against acute 
murine colitis 
A large-scale prospective nutritional study linked ω-6 fatty acid consumption to the 
development of UC.(46) However, clear results from human epidemiologic observations 
(even in prospective and well controlled) are very difficult to obtain for obvious ethical and 
technical considerations.(47) Therefore, the timing and nature of environmental factors 
critical to IBD development have remained largely unknown, as have the molecular 
mechanisms, which may uncover the environmental contribution to disease induction.(48) 
Environmental influences may trigger critical pathogenic changes at any time within an 
individual prior to the onset of disease, which can occur during a broad age range from 
fertilization to adulthood in case of IBD. Here, we examined the complex effects of 
transient high ω-6 fat diet consumption during pediatric development on the young adult 
metagenome, and immune system in a murine model of IBD. 
 
1.15 Dysbiosis-associated gastrointestinal disorders and future therapeutic options 
The commensal microbiota is a major communicator of dietary modification towards 
the intestinal immune system of the host and can rapidly change its composition upon 
nutritional challenges. Disease-associated microbiome changes can be seen in different GI 
disorders. For example, dysbiosis is found in IBDs. IBD is linked to a reduced proportion 
of Bacteroidetes and Firmicutes (with an increased Firmicutes/Bacteroidetes ratio) and an 
increased proportion of Proteobacteria compared to healthy individuals.(49) Colitis is also 
associated with a decreased abundance of Faecalibacterium prausnitzii, which is 
characterized by a notable anti-inflammatory effect.(50) Premature colonization of the 
intestine and other trigger factors together can lead to necrotizing enterocolitis (NEC), 
which is characterized by an increased abundance of Proteobacteria and 
Gammaproteobacteria and a decrease in Bacteroidetes and Firmicutes.(51) The key role is 
the pathomechanism of NEC is supported by the fact that probiotic supplemented breast 
milk can decrease the chance of developing the disease.(52) Irritable bowel syndrome (IBS) 
is a functional bowel disorder described with abdominal pain and alternating defecation 
habit. Pediatric IBS subtypes are distinguished by microbial composition differences. IBS 
DOI:10.14753/SE.2017.2023
 19 
is associated with an increased abundance of Gammaproteobacteria and pain frequency is 
linked to a greater proportion of Alistipes genus.(53) 
Reduction in microbial diversity or richness is also related to the development of 
intestinal diseases (e.g., IBDs, NEC). However, alteration of diet does not specifically mean 
beneficial effect on the colon. Monotonous dietary intake may decrease mammalian 
vulnerability against intestinal inflammation in association with microbiota separation. (54)  
In conclusion, the understand of the unique human gut microbiome and its association with 
disorders will may help developing personalized medicine and therapeutics in the future. 
However, results of the microbiome studies are based mostly on findings from 
pharmacologically treated patients. Treatments highly modify microbiome, and more 
significantly than the disease itself. (55; 56) For example, enteric dysbiosis in untreated 
IBD patients appears to be rather modest and provided unexpected findings in recent 
pediatric studies.(57)   
Microbial communities with different metabolic profiles on drugs will may modify 
the current treatment strategies. (58) Microbiome can modify drug action, metabolism and 
toxicity in the human gut and liver. Gut-associated microbes alter drug metabolism by 
modulating the drug-metabolizing enzymes activity, or change their level. Microbes also 
can directly produce enzymes that activate or degrade drug metabolites, or compete with 
molecules affecting xenobiotic metabolism. In the future, pharmacomicrobiomics will may 
be taken into consideration with pathologic and pharmacokinetic characteristics of 
individuals. 
 
1.16 The manipulation of microbiota as a possible therapeutic option in pediatric GI 
disorders 
The restoration of human microbial homeostasis may be highly beneficial for GI 
disorders, where dysbiosis present. The most complex bacteriotherapy is fecal microbiota 
transplantation (FMT). FMT is the process of stool transplantation from a healthy 
individual into a recipient. The history of FMT goes back to the 4th Century, when Ge Hong 
used human fecal suspension by mouth for food poisoning or severe diarrhea.(59) The first 
case series were reported in 1958 by Eiseman and colleagues, who treated 
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pseudomembranous colitis by fecal retention enema.(60) Immediate recovery and 
resolution of symptoms was observed within days in all patients. As our current knowledge, 
FMT is safe and highly effective for the treatment of recurrent Clostridium difficile 
infection (CDIF) in patients without complicating clinical conditions. Besides recurrent 
CDIF, there is an emerging interest to use FMT as a novel therapeutic option in patients 
with other GI disorders, such as IBD or other diseases.  
  
1.17 CDIF and FMT 
CDIF is emerging, despite the increased efforts towards prevention, improving 
diagnosis and therapy.(61) CDIF is the most commonly reported nosocomial pathogen in 
the United States (US). Epidemiologic data suggest that the CDIF-associated severe 
diarrhea is continuously increasing with a rise in hospitalization, morbidity and 
mortality.(62; 63) The latest reports showed CDIF to cause more than $1.5 billion excess 
medical costs annually in the US. (64) The incidence of pediatric CDIF is also 
increasing.(65) Recurrence of CDIF is 20-30%, which increases upon repeated infections in 
spite of new antibiotic regimens.(66) FMT has been shown to be the most effective 
treatment to date for CDIF.(67) The largest systemic review including 844 patients (76% 
diagnosed with CDIF) undergoing FMT showed 90.7% cure rates.(68) Similar cure rates 
have been shown for children,(69; 70) but microbiome analyses were performed only in a 
few cases.(71) 
 
1.18 IBD and FMT 
UC and CD are the two forms of IBD that affects about 50% of the estimated 1.8 
million people suffering from IBD in the US.(72) About 20% of IBD cases present in 
children, where the disease frequently (~40%) becomes refractory to conventional medical 
therapy within 10 years of diagnosis, leading to colectomy.(73) FMT is an emerging 
unconventional treatment for UC.(74; 75) Almost half (46%) of adult UC patients would 
consider FMT as therapeutic option (76), and both adult and pediatric patients wish to have 
it available as a treatment modality.(77) A recent meta-analysis evaluated the efficacy of 
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FMT as a treatment option for IBD patients.(78) Eighteen studies were included with 122 
patients (79 UC and 39 CD). The 9 cohort studies, 8 case studies and 1 randomized 
controlled trial demonstrated an overall 45% clinical remission over varying length of 
follow up time. According to disease severity, 37% of patients had active disease, 29% had 
moderate-to-severe disease, and 23% had mild disease. However, the review did not 
specify any correlation between FMT efficacy and IBD disease activity.  
A pediatric trial tested 5 daily FMT in mild-to-moderate UC, where 6 out of 9 
children (67%) achieved and maintained clinical remission 4 weeks after the last 
treatment.(79) However, a phase I pediatric study showed negative results following a 
single FMT via nasogastric tube.(80) The first randomized, placebo controlled trial of FMT 
as treatment for active UC was presented as an abstract at the Digestive Disease Week 
conference in 2014. Moayyedi et al. compared administration of FMT versus water-enema 
for 6 consecutive weekly treatments. They found no difference in the primary outcome of 
clinical remission after 6 weeks. However, 16 of the 27 patients in the active arm reported 
subjective improvement, and were allowed to continue receiving weekly FMT for an 
additional 6-12 weeks. With the extended therapy, 33% of patients achieved clinical 
remission.(81) Their consecutive publication indicated that FMT induces remission in a 
greater proportion of UC patients than placebo. Additionally, patients with a less than 1-
year history of UC responded better to FMT than those with more prolonged disease course 
prior to the intervention.(82) Interestingly, another recently published placebo controlled 
trial did not find a clinically significant benefit from FMT in adult UC patients.(83) This 
protocol differed significantly from Moayyedi, et al. by administering only 2 FMT 
treatments within 3 weeks by naso-duodenal delivery and they used autologous stool as 
placebo. The different outcomes from the two controlled studies may be related to the 
difference between the placebo used, the mode of delivery, the number of FMT given in 




1.19 CDIF and IBD association 
Interestingly, Clostridium difficile is an opportunistic pathogen that presents at high 
rates in patients with underlying chronic diseases and long-term hospitalization. For 
instance, the prevalence of CDIF at disease onset was 8.1% in a pediatric population with 
underlying IBD at Texas State, USA.(84) This prevalence is much higher than the general 
population. 
 
1.20 Other GI disorders and FMT 
There is an increasing attention on the association between intestinal microbiome, 
obesity and obesity-related metabolic disorders. The presented altered microbiome is 
associated with low-grade inflammation of the gut.  
Researchers described dysbiosis in patients with irritable bowel syndrome. The 
composition of microbiota represented the symptoms associated with the disease 
(constipation vs. diarrhea type IBS). (85) Additionally, 70% of the patients experienced 
improvement of their symptoms following FMT.(86) Furthermore, long-term resolution 
was seen almost half of the patients. 
The strong association between diet, host metabolism and gut microbiome demonstrates 
homeostasis and misbalance in cases with metabolic disorders. The transplantation of 
microbiome composition from a lean subject to an obese improved insulin resistance by the 
increased presence of SCFA-producing bacteria.(87) 
 
1.21 Non-GI disorders and FMT 
There is an increasing interest in the role of intestinal dysbiosis and non-
gastrointestinal disorders, and to treat patients with FMT. The gut microbiota regulates 
intestinal function, the immune and nervous systems of the intestine, and influence the 
brain by the microbiota-gut-brain (MGB) axis. This concept opens the door for a possibly 
novel therapeutic option for the treatment of neuropsychiatric disorders, chronic fatigue 






1. There is a direct link between nutrition, microbiome and host response.  
 
 
2. Postnatal exposure to different nutrients (such as cellulose or fat) has transient or 




3. Complex bacteriotherapy, such as FMT provides treatment and/or the resolution of 












3.1 Animals, diets and experimental design 
3.1.1 Cellulose supplementation study 
Our initial observations were made on C57BL/6J male mice (Jackson Laboratories, 
Bar Harbor, ME, USA) receiving (regular chow [12.5% dietary fiber]; 2920X, Harlan-
Teklad, Madison, WI, USA) or synthetic low cellulose (2.5% cellulose, LC; #102460, 
Dyets Inc., Bethlehem, PA, USA) from 30 to 90 days of age. In the consecutive 
experiments, 21-day old  (postnatal days 21, P21) C57BL/6J male mice were provided free 
access to regular chow (12.5% dietary fiber) within the same room of our animal facility for 
9 days. At P30, the mice were randomly allocated to receive synthetic low cellulose or high 
cellulose (12.5% cellulose, HC; #102532) diet for 50 days (Table 2). 
 
Table 2 The composition of the synthetic low cellulose (LC: 2.5% cellulose) and the high 
cellulose (HC: 12.5% cellulose) diets. 
  LC HC LC HC Ingredient kcal/gm grams/kg kcal/kg 
Casein 3.58 200 716 
DL-Methionine 4 3 12 
Sucrose 4 341.46 1366 
Cornstarch 3.6 242.5 172.5 873 621 
Dyetrose 3.8 90 60 342 228 
Corn Oil 9 51 459 
Cellulose 0 25 125 0 
Mineral Mix #200000 0.47 35 16.45 
Vitamin Mix #300050 3.92 10 39.2 
Choline Bitartrate 0 2 0 
Ethoxyquin 0 0.04 0 
 
Conventional chows regularly contain ~12.5% fiber (including cellulose). At P80, 
the HC animals were reversed to control (low cellulose) diet for 10 (HCR10 = P90), or 40 
days (HCR40 = P120) (Figure 2). For the microbiome studies, 10 animals in two cages 
were used for each dietary group. Those were allocated to receive either low cellulose 
(control, LC, 10 animals in 2 cages), or high cellulose diets (HC, 10 animals in 2 cages). At 
P80, 2 animals from each cage were crossed between the groups to eliminate cage bias. 
Five control animals at P80 and 5 at P90 were euthanized for tissue collection. There was 
no significant separation between these groups based upon a principal coordinates analysis 
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(PCoA) of 16S rRNA sequence information; therefore, these were grouped together as a 
single control. As for the high cellulose group, 2 animals were crossed between the two 
cages at P80. One cage was continued on high cellulose diet until P90 (HC), and the other 
cage was reversed to the control diet (low cellulose, LC) until P90 (HCR10), when those 
were euthanized for tissue collection. The discovery cohorts included 3-3 mice in two 




Figure 2 Schematic description of the cellulose feeding protocols. A: 12.5% high cellulose 
(HC) group without reversal for the purposes of colonic length and microbiota analysis.  B: 
2.5% low cellulose (LC) group. C: 10-day reversal group (HCR10). D: 40-day reversal 
group (HCR40). For the B, C and D groups DSS was administered at postnatal day 90 
(P90) and P120, respectively. (DSS: dextran sulfate sodium; R10 and R40: 10 or 40 days of 
reversal following high cellulose diet; P21/30/80/90/120, 30/80/90/120 days postnatal age). 
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3.1.2 High fat supplementation study  
P21 male C57BL/6 mice received standard rodent diet (2920X) until P30. Then, 
mice were randomly assigned to artificial diets: low 12% caloric content corn oil/linoleic 
acid: control diet, C (DYET# 102460); or to high ω-6 (40% caloric content corn oil/linoleic 
acid: ω6 or HF) (DYET# 102459) from P30 to P80. Following this 50-day period, the 
animals were reversed to C for 10 (ω6-R10) or 40 (ω6-R40) days. High milk fat, high 
cholesterol (MF) diet (DYET# 112734) was used with the same feeding protocol to 
examine fat-dependent effects. Fat to body weight ratio was interrogated on P90 and P120 
by quantitative magnetic resonance imaging (qMRI). 6-week-old Swiss-Webster germfree 
(GF) mice were derived by cesarean section under GF conditions at Taconic Farms Inc. 
(SWGF; Hudson, NY, USA) and delivered with specific GF shipping for the microbiota 
transfer experiments.  
All mice were housed in our specific pathogen free animal facility during the 
experiment. All applicable institutional and governmental regulations concerning the 
ethical use of animals were followed. The protocol was approved by the Institutional 
Animal Care and Use Committee of Baylor College of Medicine. 
 
3.2 Dextran sulfate sodium exposure 
Susceptibility to colitis was tested by administering 2% (wt/vol) (for the synthetic 
chow experiments) or 3% (for the original regular chow vs. synthetic chow observations) 
dextran sulfate sodium (DSS; MW=36000-50000, MP Biomedicals, LLC, Solon, OH, 
USA) in the drinking water at P90 or P120 ad libitum for 5 days followed by regular water 
for an additional 9 days. DSS of this molecular weight induces diffuse colitis from cecum 
to distal large bowel (88). The animals were weighed daily and colonic length 
measurements were performed at the end of the experiments following CO2 asphyxiation. 
Weight loss during DSS administration in mice has been shown to correlate well with 
molecular and histological outcome measures of colitis severity (27; 31; 89). Therefore, we 
decided to follow weight loss, colon length, and histological severity of intestinal 
inflammation as the primary outcomes measuring colitis severity in our DSS experiments. 
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3.3 Tissue collection and histological analysis 
At the end of the feeding periods, mice were sacrificed by CO2 asphyxiation 
between 11:00 AM and 2:00 PM without any previous food restriction. The colons were 
placed on ice, transected longitudinally, cleansed from feces, washed with ice cold normal 
saline, followed by the collection of colonic mucosa with a microscope slide (90) 
(excluding the cecum). The mucosal scrapings were flash frozen on dry ice, and stored at -
80oC as earlier described (31). 
For histological analysis, additional colonic samples were transected and processed 
for standard hematoxylin-eosin (HE) staining following fixation in 10% formaldehyde. 
Histological severity of intestinal inflammation was determined by a blinded pathologist 
based upon tissue damage grade and the presence of inflammatory cells. (54) 
Morphometric analyses (crypt length, surface area) were performed with Olympus 
DP2-BSW program on transected proximal (post-cecal) colonic specimens. 
 
3.4 Microbiota transplantation in mice 
Cecal contents were pooled from ω6-R40 or C120 littermates. Cecal extracts were 
suspended in phosphate-buffered solution (PBS, 2.5 ml per cecum) and were administered 
orally by gavage (0.1 ml per mouse) immediately to sterilely packed 6-week-old SWGF 
male GF mice (Taconic, Hudson, NY, USA) as described by Vijay-Kumar et al.(91) 
Transplanted mice were fed with control diet for 5 days, and then 3% of DSS was given to 
induce acute colitis. Body weight was measured daily. The animals were euthanized and 
tissues were collected as above.   
 
3.5 DNA extraction and analysis of microbiome  
Colonic mucosal samples were submitted to the Texas Children’s Microbiome 
Center (TCMC, Houston, TX, USA) for DNA extraction and sequencing. Community 
DNA was extracted from each specimen using the PowerSoil DNA isolation kit (Mo Bio 
Laboratories, Carlsbad, CA, USA), following the HMP modifications (2) to the 
manufacturer's instructions.  The resulting DNA was quantitated using both a NanoDrop-
DOI:10.14753/SE.2017.2023
 28 
1000 spectrophotometer (NanoDrop, Wilmington, DE, USA) and Qubit fluorometer (Life 
Technologies Corporation, Carlsbad, CA, USA). Barcoded universal primers 357F (5’-
CCTACGGGAGGCAGCAG-3’) and 926R (5’-CCGTCAATTCMTTTRAGT-3’) were 
utilized to amplify the V3-V5 region of the 16S rRNA gene. The discovery study utilized a 
different set of PCR primers (28F [5’-GAGTTTGATCNTGGCTCAG-3’] and 519R [5’-
GTNTTACNGCGGCKGCTG-3’] amplifying the V1-V3 region of the 16S rRNA). Each 
library construct was then processed and purified for 454 sequencing. Sequencing was 
performed on the Roche GS FLX 454 sequencer (454 Life Sciences, Branford, CT, USA).  
Sequence data were parsed by barcode and quality filtered using QIIME (version 
1.3.0) (92), as implemented in the Genboree Microbiome Toolset (93). Sequences shorter 
than 200 bp lengths, having average quality scores less than 20, harboring ambiguous base 
calls, or having mismatches to their barcode or sequencing primer were excluded from 
further analysis. Both the barcodes and sequencing primers were trimmed away, and the 
remaining sequences from the control and treatment groups were pooled and assigned to 
operational taxonomic units (OTUs) at a similarity cut off of 97% using Cd-hit (94). The 
data set was screened for potential chimeras using the ChimeraSlayer algorithm (95), and 
all potential chimeras were excluded from downstream analysis.  Identities were assigned 
to each OTU using the Ribosomal Database Project Classifier (96). 
Prior to the calculation of diversity metrics or comparison across treatments, the 
sequence libraries were randomly subsampled to achieve even sampling depth (subsampled 
depth = 3634 sequences per library). All results presented here were determined using our 
subsampled sequence libraries. Community similarity was evaluated across treatments 
among treatments using principle coordinates analysis (PCoA) of OTU data. PCoA plots 
were generated using weighted Unifrac distances, as calculated in QIIME.  
Sequence libraries were also evaluated for potential differences in composition 
using two-tailed Mann-Whitney U-tests and false discovery rate correction for multiple 
comparisons in Genespring GX (version 12.0) (Agilent Technologies, Santa Clara, CA, 
USA). A stratified approach was used, first identifying OTUs that differed significantly 
with respect to the treatment groups and controls, then exploring these differences further in 
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the context of the R10 and R40 treatment, with the goal of identifying changes that may be 
transient or longer-lasting.  
 
3.6 Flow cytometry 
To conduct lymphocyte population analysis, mesenteric lymph nodes (MLNs) and 
spleens (SPLs) underwent mechanical disruption, erythrocyte lysis and preparation for flow 
cytometry as described previously.(97) Lymphocytes were labeled for the markers cluster 
differentiation (CD) 4 and C-X-C motif ligand chemokine receptor (CXCR) 5 (BD 
Biosciences, San Diego, CA, USA). Flow cytometry was performed using a FACSCanto 
instrument (BD Biosciences, San Diego, CA, USA), and the data was analyzed using 
FlowJo software (Treestar, Ashland, OR, USA).  
 
3.7 In vivo chemokine blocking  
C57BL/6J mice were treated with 0.2 mg of neutralizing C-X-C motif ligand 
chemokine (CXCL) 13 antibody (ab) (#MAB470; R&D Systems) or isotype control ab 
(#MAB006; R&D Systems, Minneapolis, MN, USA). Both mouse abs were delivered by 
intraperitoneal injection in 1 mg/ml concentration dissolved in PBS. To examine the effect 
of CXCL13 ab on DSS-induced colitis model, abs were administered on the first, third and 
fifth day (3 times) after initiating 3% DSS.  
 
3.8 Human samples and Enzyme-linked Immunosorbent Assay (ELISA) 
 33 pediatric patients were recruited prior to endoscopy following informed consent 
though the institutional review board (IRB) approved tissue bank of the Pediatric 
Inflammatory Bowel Disease Consortium Registry at the Baylor College of Medicine (H-
17654). Sera of 12 UC, 11 CD and 10 healthy controls (C) were used for quantification of 
circulating CXCL13 levels. Pediatric controls included children who underwent 
colonoscopic evaluation for diagnoses of hematochezia, diarrhea, or abdominal pain, but 
whose endoscopy was grossly and histologically normal. BD Vacutainer® CPT™ Cell 
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Preparation Tube with Sodium Citrate was used to isolate peripheral blood mononuclear 
cells (PBMCs) from peripheral blood (PBL). PBLs were centrifuged at 1000x g for 10 min 
and stored at -80oC. QuiAmp DNA mini kit (Qiagen, Valencia, CA) was utilized on the 
isolated PBMCs to retract DNA. Plasma concentrations of CXCL13 were quantified by 
Quantikine ELISA methodology according to the manufacturer’s instructions (#DCX130; 
R&D Systems, Minneapolis, MN, USA). All samples were measured in duplicate. Color 
intensity of the assay was measured by a standard ELISA microplate reader. Color intensity 
correlates with the amount of bound CXCL13. Quantikine kit standards were used for 
generation of standard curves. 
 
3.9 FMT protocol  
3.9.1 Subjects with recurrent CDIF 
Ten pediatric patients (5 females and 5 males; 2-16 years of age [y], average 9.3 y) 
with recurrent CDIF received FMT under an IRB approved protocol (Table 3). The 
experimental nature of FMT was highlighted during consenting.  
 
Table 3 Characterization of patients received fecal microbiota transplantation. Patients 
highlighted had no major underlying diseases and were evaluated for further analysis.  
Pt G R E Age (y) Significant complicating disease Prior CDIF treatment 
1 M W NH 15 ulcerative colitis vancomycin  
2 F W NH 16 
 
vancomycin and metronidazole  
3 F W H 15 cerebral palsy vancomycin  
4 M W NH 4 
 
vancomycin  
5 M W NH 2 
 
vancomycin  
6 F W NH 2 heart transplant vancomycin  
7 M W NH 6 Crohn’s disease Vancomycin 
8 F W NH 2 infantile spasm vancomycin  
9 M W NH 15 
 
vancomycin  
10 F W NH 16 mild ulcerative colitis vancomycin  
(E: ethnicity; F: female; G: gender; H: Hispanic; M: male; NH: non-Hispanic; Pt: patient; 
R: race; W: White; y: years) 
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Three patients had IBD (2 UC and 1 CD), 1 had heart transplant, and 2 had significant 
neurologic impairment as underlying conditions (Table 3). All patients received at least 1 
course of metronidazole (10-14 days) and vancomycin orally. They all had 
recurrent/ongoing symptoms in spite of at least 2 courses of antibiotics. Eight out of ten 
patients received vancomycin until one day prior to FMT; one patient had finished 
vancomycin therapy 2 weeks before FMT, and one 3 weeks prior to FMT.  
 
3.9.2 Subjects with UC 
 Subjects were recruited from the patients treated by the Pediatric Gastroenterology, 
Hepatology, and Nutrition Section at Baylor College of Medicine/Texas Children’s 
Hospital. Only patients whose clinical, endoscopic and histologic findings supported the 
diagnosis of UC were recruited. Only steroid, thiopurine, or biologic agent dependent 
patients were included following informed consent (i.e. “immunotherapy” dependent). 
Enrollees had to test negative for Clostridium difficile toxin by polymerase chain reaction 
(PCR), or enzyme immunoassay (EIA), and agree to withdraw all medications prior to and 
during the trial. They also had to agree to a pre-treatment surgical consultation and 
acknowledge the potential need for colectomy, if disease exacerbations cannot be 
controlled by conventional medical therapy.  
 We analyzed the clinical and microbial data of 3 patients from our first pilot study 
(Table 4) and 6 patients from our second Investigational New Drug (IND)-linked phase 1 














Table 4 Patient characteristics and clinical outcomes after sequential FMT from our first 



























At Dx Before FMT 
After 
FMT 
1 (16y M) Pancolitis 2 IFX 0 30 65/70 (93%) 0 261 126 IFX 
2 (15y M) Pancolitis 2 6MP 1 25 58/58 (100%) 0 159 80 
PRED 
FMT 




(Dx: diagnosis; F: female; IFX: infliximab; M:male; 6MP: 6-mercaptopurine; PRED: 
prednisone; Tx: therapy) 
 
Table 5 Patient characteristics, premedication and donor characterics in our IND phase 1 
clinical study.  
Study 









Time between diagnosis and 
first FMT (months) 
P001* M W NH 16 Prednisone D001 13 41 (*29) 
P002 F W NH 18 Prednisone D002 17 7 
P003# F W H 15 Prednisone D001 13 18 (#6) 
P004 M W NH 20 Prednisone D001 16 43 
P005 M W NH 17 Prednisone D001 17 3 
P006 M W NH 13 Prednisone D001 11 22 
D001 M A/I NH 37     
D002 F A/I NH 30     
(D: donor; E: ethnicity; F: female; G: gender; H: Hispanic; ID: identification; IFX: 
infliximab; M: male; 6MP: 6-mercaptopurine; NH: non-Hispanic; PRED; prednisone; Pt: 
patient; R: race; W: White; y:years) 
3.9.3 Donor recruitment  
 Healthy adult stool donors (between 18 and 45 years of age) were recruited by the 
research staff following informed consent. Donors were asked to volunteer for the 
screening (pass a health questionnaire, serologic and stool tests and regularly supply stool 
samples according to the study protocol.  
 
3.9.4 FMT preparation 
 The stool preparations were performed in the TCMC. This facility operates under 
Good Laboratory Practice (GLP) and is part of the clinical enterprise in the Department of 
DOI:10.14753/SE.2017.2023
 33 
Pathology, accredited by the College of American Pathologists (CAP) and certified by 
Clinical Laboratory Improvement Amendment (CLIA). Standard Operating Procedures 
(SOPs) on fecal specimen preparation and for decontamination procedures for biosafety 
cabinets and equipment were followed before and after fecal preparation.  Freshly collected 
stool specimens from the healthy adult donor (within 2 hours of passing) were delivered on 
ice for processing. Specimens were aliquoted to ~50 g aliquots, and cold sterile normal 
saline solution (NSS) was added prior to homogenization in a strainer bag with 500-µm 
pore size (Seward Laboratory Systems Inc., Port Saint Lucie, FL) using the Smasher 
Laboratory Blender/Homogenizer (AES CHEMUNEX Inc., Cranbury, NJ). Sterile glycerol 
was added to filtered homogenized stool specimens containing the fecal microbiome at a 
final concentration of 10% according to Hamilton et al.(98) Stool preparations were 
immediately stored at -80˚C until transplantation or analysis. All stool preparations were 
labeled with an expiration date 8 weeks from the date of preparation. At each FMT 
treatment, fecal preparations were rapidly thawed at 35˚C in a water bath and used within 
15 minutes. Sterile NSS was used as a diluent to reach the final volume of 250 ml from 
50mg of original stool prior to delivery. 
 
3.9.5 FMT treatment protocol in CDIF patients 
Patients received filtered, frozen-thawed fecal preparation from a single, screened, 
standardized (D002, 9 patients), or a self-designated donor (D005-father of patient 6) 
through colonoscopy, followed by enema or nasogastric consecutive FMT, if clinically 
indicated. The donor screening and process was approved by the US Food and Drug 
Administration and published previously.(99) The CDIF patients received the therapy only 
one time (or a second time if there was no clinical improvement in their condition. 
 
3.9.6 FMT treatment protocol in UC patients 
UC patients received a sequential therapy of more FMTs: 
Initial colonoscopy and FMT treatment (Day 1): At the time of colonoscopy, an assessment 
for macroscopic colitis using the Mayo classification was performed. Biopsies were 
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obtained from the rectosigmoid and cecum in an ascending fashion for routine 
histopathology and research purposes. Following mucosal sampling, subjects underwent 
FMT with 250 ml of thawed stool preparation, 1/3 of which was endoscopically 
administered into the terminal ileum and 2/3 into the right colon as targeted site as found 
feasible by Brandt and colleagues.(100) 
Subsequent FMT Treatments: The duration of FMT therapy was planned to be 12 weeks.  
Days 2 through 14: Subjects came to the ambulatory clinic daily for clinical symptom 
evaluation and fecal retention enema administration (60-250 ml rectally [as tolerated] with 
retention for at least 30 minutes).  
Days 15 through 28: Enemas were given 3 times a week on weeks 3 and 4 of the protocol.   
Days 29-84 (2 to 3 months): Enemas were given weekly for a total of 3-8 weeks (less than 
8 secondary to the cessation of the protocol according to the FDA mandate).  
During the IND study (P001-P006, this protocol does not involve the first 3 patients from 
the pilot study), monthly enema was provided up to a year. 
As supportive care, patients were allowed to take 4 mg (2 tablets of over the counter 
Imodium) loperamide by mouth 15-30 minutes prior to enema treatments to help retain the 
preparation. This dose of loperamide is appropriate for the age group. Loperamide is over-
the-counter and FDA approved for the treatment of inflammatory bowel disease associated 
diarrhea.  
Response and progression was monitored by PUCAI during the protocol. The clinical 
symptoms survey was performed prior to each enema delivery and a disease progression 
table was recorded for each enrolled patient. 
 
3.9.7 Sample collection 
Stool samples of CDIF patients were collected the day prior FMT and 8-9 weeks 
following treatment on a follow-up visit. Select patients provided additional samples.  
Samples from UC patients were collected on the day prior to FMT, two weeks after the last 




3.10 Human microbial data analysis 
The fecal microbiome was characterized using 454 pyrosequencing of the bacterial 
16S rRNA gene on samples. Stool samples were processed by the TCMC for DNA 
extraction, sequencing and microbial data analysis (same as mentioned above in our mice 
protocol).  
Given variation in sequencing depth, the 16S rRNA gene libraries were sub-
sampled to an equal depth (i.e., 1900 sequences per library) prior to the evaluation of 
richness or calculation of diversity indices, including the Shannon diversity index and 
unweighted UniFrac distance measures. The results from the microbiome characterization 
of the donor were compared to the patient’s microbiome prior and after transplantation.  
 
3.11 RNA sequencing and analysis 
RNA samples from colon biopsies were QCed by spectrophotometry (NanoDrop-
1000 Spectrophotometer, Thermo Fisher Scientific, Waltham, MA, U.S.A.) and 
microfluidic electrophoresis (Experion Automated Electrophoresis System, Bio-Rad 
Laboratories, Hercules, CA). PolyA-selected libraries were prepared from total RNA 
samples with TruSeq RNA Sample Preparation Kits (Illumina, San Diego, CA). Cluster 
generation was performed with Illumina TruSeq SR Cluster Kits v3 - cBot – HS, in a cBot 
Cluster Generation System and 100 bp paired-end-sequencing using Illumina TruSeq SBS 
Kits on an Illumina HiSeq 2000 Sequencing System resulting in mean sequencing depth of 
160 million (101-213 million) reads per sample. CASAVA software (Illumina) was used to 
convert raw read data to fastq format. Sequencing reads were trimmed for quality (q < 20) 
and adapters and then aligned to the human genome (GRCh37/hg19) using Tophat29. 
Cufflinks10 was used for estimation of transcript abundances based on Fragments Per 
Kilobase of exon per Million fragments mapped (FPKM). Differential expression analysis 
was carried out using Cuffdiff, which calculates a test statistic based on the log ratio of a 
gene's expression in two conditions against the log of one. Multiple testing correction at a 





The biopsy specimens were examined by a GI pathologist, who was blinded to the 
previous reported histology reports. The specimens were fixed in 10% neutral buffered 
formalin immediately following endoscopy.  The tissue samples were routinely processed 
and paraffin embedded. Paraffin sections (3 micron) were cut and HE stained with eight 
tissue sections on one slide. Duplicated 3-micron sections were stained for histone (H3) via 
immunohistochemistry using a polyclonal rabbit anti-human histone (06-570; Millipore, 
Billerica, Massachusetts). After pretreatment with HIER1 (Bond Epitope Retrieval Solution 
1) for 30 minutes at 100 degree Fahrenheit, the specimens were incubated with the primary 
antibody dilution 1:800 at room temperature for 15 minutes. The detection system used was 
the Novocastra Bond Polymer Refine Detection System (biotin-free, peroxide conjugated) 
from LEICA, Newcastle upon Tyne, United Kingdom with diaminobenzidine 
tetrahydrochloride (DAB) as the chromogen and HE as the counterstain. 
 
3.13 Additional statistical analysis 
Nonparametric, two tailed Mann-Whitney-tests was utilized for richness calculation; 
parametric, two-tailed Student’s T-test and correlation calculations were used in the 
analyses of OTU number changes and group comparisons. The statistical significance was 
declared at p<0.05. Error bars represent standard error of the mean (60). A parametric, two-
sided Student’s two-sample t-test was used in the analysis of shared similarities and 
distances. Spearman correlation coefficient and level of significance was calculated in 
Prism4.03 between Mayo score and length of clinical remission. The statistical significance 





4.1 CELLULOSE SUPPLEMENTATION STUDIES IN MICE 
4.1.1 Increased severity of DSS colitis on a synthetic, low fiber diet 
Chemical colitis in C57BL/6J mice is usually induced by transient exposure to 3-5% 
DSS (88; 101). When we initiated 3% DSS treatment in animals that received a synthetic, 
low cellulose (2.5% cellulose, LC) diet, they lost excessive weight necessitating early 
euthanasia (Figure 3A). Therefore, mice on the LC diet had significantly increased 
susceptibility to chemically induced colitis compared to animals on regular chow (12.5% 
dietary fiber). Based on our findings, we utilized 2% DSS treatment to induce colitis in our 
further experiments involving low cellulose diets. 
 
 
Figure 4 Increased severity of colitis and decreased colonic lengths in P90 mice fed by a 
synthetic diet [low cellulose (2.5%, LC) as fiber] compared to regular chow (12.5% dietary 
fiber). Upon 3% DSS challenge (A, n=8-10), the animals on the LC diet lost significantly 
more weight than on regular chow. On the seventh day, the experiment had to be 
terminated for severe weight loss in the LC group. In independent experiments where the 
mice did not receive DSS (B, n=14-40), colonic lengths of mice fed the synthetic diet were 





Upon comparing large intestinal lengths between mice receiving regular chow and 
our synthetic (LC) diet, we recognized that colons were significantly shorter on the 
artificial diet (Figure 3B) without any previous exposures (such as DSS). Since dietary 
fibers and cellulose specifically have been shown to promote intestinal lengthening (trophic 
effects) in rodents (39; 102), we postulated that the low cellulose content of the synthetic 
diet may have been responsible for the observed shorter baseline colon lengths (leading to 
smaller colonic surface area) and increased susceptibility to DSS colitis (secondary to 
increased DSS to relative colonic surface, i.e. higher concentrations of the chemical irritant 
at the mucosa).  
 
4.1.2 Transient trophic and anticolitic effects of cellulose supplementation  
Dietary fibers have been observed to decrease colitis severity in acute and chronic 
rodent models (103-105). However, the means by which this effect is accomplished, and 
whether all fiber types have such anti-inflammatory properties, remains questionable. We 
were particularly interested if dietary cellulose supplementation by itself could decrease 
DSS colitis severity and how persistent such effects may be. Consequently, the cellulose 
content of our synthetic diet was selectively increased (high cellulose, HC) and fed to the 
animals during the pediatric period (P30-P80 (106)). Thereafter, the mice were reversed 
back to the LC diet for 10 (high cellulose reversed 10 days: HCR10 = P90 total), or 40 
(HCR40 = P120 total) days to examine the persistence of any anticolitic effect induced by 
pediatric cellulose supplementation. The pediatric period is highly relevant with respect to 
the nutritional and developmental origins of IBD since the disorders most commonly 
present in young adulthood (31). Colons were significantly longer in mice fed a high 
cellulose diet even after 10 days of reversal compared to controls (Figure 5A). Remarkably, 
the large intestines were similar in length compared to control following 40 days of reversal 
(Figure 5C). The severity of DSS (2%) colitis correlated inversely with baseline colonic 
lengths in the feeding groups. Mice reversed for 10 days from the high cellulose diet 
(HCR10) were protected compared to the controls (LC) (Figure 5B). Colitis susceptibility 
was similar between the 40 day reversal (HCR40) and LC groups (Figure 5D). The severity 
of histological inflammation upon DSS challenge also decreased (p=0.016) in the HC 
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dietary group compared to controls (LC) supporting the findings on weight loss and colonic 
shortening (Figure 6).  
 
 
Figure 5 Transient colonic trophic effect and protection against dextran sulfate sodium 
(DSS) colitis upon cellulose supplementation. A. Colons were significantly longer in 
animals receiving 12.5% cellulose supplemented diet (HC). This trophic effect persisted 
after 10 days of reversal (HCR10) from the 12.5% cellulose to 2.5% cellulose diet (LC 
P90) [n=40-10-15]. B. Other mice were exposed to 2% DSS (as opposed to 3% in Figure 1, 
due to the increased sensitivity of mice to DSS on the low cellulose diet) in their drinking 
water at P90 for 5 days then received regular water. Mice reversed for 10 days (HCR10) 
from the high cellulose (12.5%) diet were protected (less weight loss) against DSS 
compared to controls (LC P90) [n=7-10 per group]. The histological score confirmed our 
results: high cellulose supplemented group had decreased severity of colitis upon DSS 
challenge (See Figure S2). C. The cellulose supplementation induced trophic effect was lost 







P120) [n=8-8]. D. Colitis susceptibility was also similar between the 40 day reversal 
(HCR40) and control groups (LC P120) [n=7-10 per group]. 
 
 
Figure 6 Histological severity of colitis in a validation experimental group.  Colitis severity 
was significantly  (U test p=0.016) decreased in the  12.5% high cellulose (HCR10) group 
compared to controls (low cellulose, LC). N=5. Cellulose supplementation was given 
between postnatal day 30 to 80 , then DSS treatment was administered for 5 days. We did 





Figure 7 Transected proximal colons from LC (left) and HC (right) mice at P90. Note the 




crypts in HC compared LC. The surface area increase secondary to this morphological 
change was calculated to be 20% in HC compared to LC (magnification x40). 
 
Morphometric analyses on representative proximal colonic samples from HC and 
LC (Figure 5A) mice showed that HC leads to significant (p<0.001) elongation of crypts 
leading to a 20% increase in transectional surface area (Figure 7). The overall average 
colonic surface area increase upon cellulose supplementation was calculated to be around 
20%.  
 
4.1.3 Microbial diversity and composition changes following cellulose 
supplementation  
Mucosa associated microbes may be more important in gut homeostasis and 
inflammation than luminal ones (45). The effect of different fibers on the metabolic activity 
and composition of the gut microbiome was observed both in fecal samples and in in vitro 
models (37; 107; 108). Nevertheless, the consequence of dietary fiber (including cellulose) 
supplementation on the colonic mucosal microbiome in mammals has not been studied, 
especially with high-throughput methodologies. Therefore, we examined if dietary 
cellulose supplementation may affect the colonic mucosal microbiome. The persistence of 
effects on the gut microbiome 10 days following a decrease in cellulose consumption was 
also studied in a discovery and a validation cohort.  
 A variety of microbial taxa were detected within the colonic mucosa of mice on the 
HC, LC, and HCR10 diets. Although several could be identified to genus level, the majority 
could not be identified confidently beyond the family level.  Several bacterial families were 
detected in increased quantities in the colonic mucosa of mice on the HC diet compared to 
LC (Figure 8A). This fiber-dependent augmentation of microbial richness was persistent up 
to 10 days of reversal to the low cellulose diet (HCR10). A tendency toward increased OTU 
richness was also observed in the HC group compared to LC, but was diminished by 10 
days reversal (Figure 8B). The HC OTU richness was on average 242 OTUs, while HCR10 




Figure 8 Cellulose related increase in microbial richness. A. High cellulose (12.5%, HC) 
diet stimulated a significantly increased number of detectable families compared to low 
cellulose (2.5%, LC). This separation persisted 10 days following reversal (HCR10). B. 
The OTU counts of species were slightly increased in the HC group compared to LC, but 
not in the reversal group (HCR10). p values represent two tailed non-paired T test. 
 
PCoA showed a distinct separation between the HC and LC group communities 
(Figure 9). HCR10 samples clustered between the LC and the HC microbiome, indicating 
partial reversal of the cellulose-induced separation following 10 days on low cellulose diet. 
Cage effects did not influence community separation within the groups.  
The most abundant family level taxon changes mirrored the PCoA results (Figure 
8), in which the HC and LC groups appeared to be distinctly different from one another, 









Figure 9 Cellulose induced shifts in the composition of the gut microbiome. Principle 
coordinates analysis (PCoA) shows separation of the colonic mucosal microbiome on high 
cellulose diet (● high cellulose [12.5% ]; n=5). This separation decreased by 10 days of 
reversal (▲10 days reversal from high cellulose diet [HCR10]; n=5) compared to controls 
(■ control [2.5% cellulose] diet; n=10). Individual animals did not show separation 
depending on cage origin.  
 
Two phyla (Actinobacteria and Tenericutes) were significant increased and 
diminished in abundance, respectively in the HC group compared to control (LC). Only 
members of the phylum Actinobacteria showed persistently decreased abundance after 10 
days of reversal (Table 6).  An example of this can be seen in Figure 10, where an 
Olsenella-like OTU (i.e. OTU 898) demonstrated significantly decreased abundance in the 




Figure 10 Boxplots depicting shifts in OTU abundance following diet reversal. A stratified 
approach was used to identify transient changes in OTUs. Each of the OTUs depicted 
differed significantly between the HC and the LC treatment, as well as between the HCR10 
and the HC groups, or between the HCR10 and the LC groups. 
 
Our discovery cohort indicated a decrease in the family level abundance differences 
between the HC and the LC groups following 10 days of reversal to the LC diet from HC 
(Figure 11). The validation experiments conformed these results. There were 10 
distinguishable families with significant abundance difference between the HC and the LC 
groups. This number decreased to 6 families by 10 days of reversal (HCR10) with overall 
higher p values than in the HC-LC comparisons (data not shown). Persistent family 
abundance differences in the HC and the HCR10 groups, when compared to the LC group, 
were in Coriobacteriaceae (decrease), Peptostreptococcaceae and Clostridiaceae (increase) 





Figure 11 A. Relative abundance of the most common families within the colonic mucosal 
samples of the discovery group. Altered relative abundance of bacterial families was 
presented upon high cellulose (HC) diet compared to control (Low cellulose, LC). This 
alteration diminished following 10 day reversal (HCR10).  B. Relative abundance of the 
five most common (and the unclassified) families within the colonic mucosal samples. The 
HC group is more different from the LC than the 10 day reversal dietary group (HCR10). 
C. Abundance variation in the 10 most abundant bacterial families between the dietary 
groups. A trend for reversal in abundance can be seen in most of the taxa by 10 days of 
reversal (HCR10) from the high cellulose diet (HC) in relationship to the low cellulose 
(LC) group. 
 
Table 6 The effects of cellulose supplementation on colonic mucosa associated bacterial 
phyla and families. Actinobacteria was significantly modified in abundance secondary to 
increased amounts of dietary cellulose (HC: high [12.5%] cellulose vs. LC: low [2.5%] 
cellulose), and separated at 10 days of reversal (HCR10) from the LC group as well. There 
were three families (Coriobacteriaceae, Peptostreptococcaceae and Clostridiaceae) with 
significant and persistent abundance difference on HC and HCR10 compared to controls 
(LC) following the temporary cellulose supplementation. p values represent two tailed non-
paired T test, U values represent two tailed non-parametric Mann-Whitney U-test (ns: not 
significant, na: not applicable). 
    HC vs. LC HCR10 vs. LC 
 LC HC HCR10 p U P U PHYLUM        Actinobacteria 0.365988 0.115575 0.088057 0.010551 0.0193 0.002612 0.0007 
FAMILY        Coriobacteriaceae 0.365988 0.071547 0.055036 0.002391 0.0007 0.001153 0.0007 
Peptostreptococcaceae 0 1.733627 0.093561 2.77E-08 na 0.008005 na 
Clostridiaceae 0.156852 1.056687 1.172262 0.001377 0.0013 0.047661 ns 
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4.2 ω-6 FAT DIET REVERSAL AND ITS EFFECT IN MURINE STUDIES 
4.2.1 Reversal from ω-6 fat diet protected against colitis  
Mice fed for 50 days with high ω-6 fat diet exhibited significantly higher body fat 
compared to controls. This body composition difference was lost following 40 days of 
reversal (ω6-R40; Figure 12A). In the meantime, dietary reversal from high ω-6 fat diet 
induced prolonged protection against DSS-induced colitis. The ω6-R40 animals displayed 
lower body weight loss (Figure 12B) and lower histologic severity of colitis than control 
(Figure 12C-E). These findings were replicated in independent experiments. 
 
 
Figure 12 ω-6 fat diet dependent protection against colitis. (A) qMRI measurements 
showed significantly increased fat composition following ω-6 fat dietary intake in mice 
(ω6-P80) compared to controls (C-P80), which diminished after 40 days of reversal (C-
P120, compared to ω6-R40). (n=14-8-15-11, respectively). (B) However, 5 days following 
5-day-DSS-exposure (2%), the ω6-R40 group lost less weight compared to control (C-
P120) (n=5-5). (C-E) ω6-R40 group had milder tissue damage upon DSS challenge 
compared to controls. (C) Histological severity of colitis was higher in control compared to 
ω6-R40. (D-E) A greater degree of tissue damage and inflammatory cell infiltration was 
observed in control colons compared to ω6-R40 (magnification x200). Error bars represent 










4.2.2 Protection against colitis was ω-6 and reversal dependent 
We were interested to investigate whether the colitis protective effect was specific 
to ω-6 or whether the transient pediatric consumption of any type of fat would induce a 
similar phenotype. Using a high milk fat (MF) diet instead of ω-6 fat, we observed the 
opposite response. The transiently MF fed mice lost more weight upon DSS challenge than 
controls (Figure 13A). Thereafter, we sought to establish whether exposure to high ω-6 is 
sufficient to protect against colitis, or if dietary reversal to control diet is necessary to 
establish the phenotype. Without dietary reversal, mice had a similar degree of weight loss 
as controls upon DSS challenge at both P90 (60 days of ω-6 feeding) and P120 (90 days of 
ω-6 feeding) (Figure 13B-C). 
The velocity and extent of weight loss was similar in both the ω-6 and milk-fat 
reversal groups (Figure 13D).  
 
 
Figure 13 Protection against colitis is ω-6 fat dependent and associated with reversal. (A) 
Using milk fat (MF) diet instead of ω-6 fat diet, the reversal group (MF-R40) developed 
more severe colitis compared to control (C-P120). (n=5-5) (B-C) ω-6 high fat dietary group 





significant difference in body weight changes between the dietary groups (P90; n=7 or 
P120; n=5). (D) Weight changes following dietary reversal (at p80) showed similar velocity 
of weight loss in both of the different fat supplemented groups (MF or ω-6) within 10-13 
days being on control diet followed by weight gain. Error bars represent standard error of 
the mean (60). **p<0.01, unpaired t test. 
 
4.2.3 ω6-reversal did not affect other models of colitis 
We examined the effects of the transient high ω-6 feeding in both IL-10-/- 
mice,(109) and in the adoptive transfer model of CD4+, CD45RBhi+ T cells into Rag1-/- 
mice.(110) The nutritional intervention did not have any significant effect on these chronic 
models of colitis (data not shown). 
 
4.2.4 The gut microbiome of ω6-reversed mice transmitted the colitis suppression 
We were interested to elucidate whether the gut microbiome of ω6-R40 mice may 
be functionally modified to transfer protection against chemically induced colitis. We 
collected fecal material from transiently high ω-6 fat fed and control mice and transferred it 
into germfree mice (fecal microbiota transplantation). The transplanted animals were then 
exposed to DSS to examine the effects of the dietary intervention induced microbiome 
changes on acute colitis. The recipients of the ω6-R40 microbiome had a 100% survival 
rate compared to a 60% survival in controls (Figure 14A).  Colons retained their lengths 
and exhibited less severe colitis even in the survived ω6-R40 mice compared to controls 
(Figure 14B-C).    
 
 
Figure 14 Microbial changes following transient ω-6 fat diet. (A-C) Germfree murine 
recipients of feces from the reversed high fat dietary group (ω6-R40) were protected against 
colitis. After initiation of DSS treatment, (A) increased mortality in the control group was 
A B C 
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observed (C-P120) compared to the ω6-R40 group. (B) Histological colitis severity was 
less and (C) colons length remained longer in ω6-R40 compared to C-P120. 
 
4.2.5 The microbiome of ω6-reversed mice segregated from control 
Analysis of the gut microbiome revealed separation between the dietary groups. 
Unweighted principal component analysis of colonic mucosal microbiomes showed a 
segregation of mice transiently fed with high ω-6 fat diet from controls even after 40 days 
of dietary reversal (Figure 15D). Upon examination of the 20 most abundant genera in the 
microbiomes (Figure 15E), only the Enterococcus genus showed a significant decrease in 
ω6-R40 group compared to control (p=0.0079). At the species level, the abundance of 
Hespellia porcina, Enterococcus faecalis, Clostridium innocuum and Oscillibacter species 
decreased in the reversal group (ω6-R40) compared to control (p=0.0317, 0.0159, 0.0159 
and 0.0159 respectively) (table not shown). 
 
Figure 15 (D) Unweighted principal component analysis (PCA) of the colonic mucosal 
microbiomes showed separation between the experimental groups, which persisted after 40 
days of reversal from high ω-6 fat diet. (n=5-5). (E) Genera (most abundant 20) level 
microbiome separation between the ω6-R40 and control groups. Only Enterococcus 






4.2.6 Cxcr5+ CD4+ T cells were suppressed in ω6-reversed mice 
  We next explored how the colonic epithelium/mucosa was influenced by a transient 
consumption of high ω-6 fat diet. DNA methylation specific amplification microarrays 
(MSAM) and gene expression microarrays on isolated colonic mucosa were employed to 
interrogate persistent diet induced epigenetic changes.(33) Even though these high 
throughput approaches did not yield statistically significant results (data not shown), we 
observed a small reduction of Cxcr5 expression in the colonic mucosa of ω6-reversed mice. 
We hypothesized that Cxcr5 transcripts may have originated from mucosa associated 
leukocytes derived from mesenteric lymph nodes (MLNs) rather than from epithelial cells 
(which generally comprise >90% of the cell population in our colonic mucosal scrapings). 
Flow cytometric analysis of different T cell subsets confirmed a significant reduction in the 
numbers of Cxcr5+ CD4+ T cells in the MLNs of ω6-R40 animals in independent 
experiments (Figure 16A-B).  
 
4.2.7 Cxcr5 ligand B-lymphocyte chemo-attractant (or Cxcl13) modulated colitis 
susceptibility  
The observed decrease in the number of Cxcr5+ CD4+ T cells implicated the 
importance of Cxcr5 and its ligand B-lymphocyte chemo-attractant (or Cxcl13) in murine 
acute colitis. Therefore, we examined the effect of Cxcl13 antibody (ab) treatment in the 
severity of DSS-induced colitis. Cxcl13 ab treated mice had a tendency to loose less weight 
during DSS challenge (Figure 3C). Additionally, we observed increased colonic length and 
decreased colitis severity in the Cxcl13 ab treated mice compared to isotype controls 
(Figure 16D-E), indicating that the inhibition of Cxcr5 signaling is protective against 
murine acute colitis. 
 
4.2.8 CXCL13 levels in the plasma of IBD patients 
Finally, we sought to establish whether the CXCR5-CXCL13 pathway may be 
activated in human IBD based on our murine experiments. CXCL13 was measured in the 
blood of untreated pediatric patients with UC, CD, and controls. Plasma samples were 
collected at the time of diagnostic endoscopy. Plasma concentration of CXCL13 was 
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significantly elevated in children with treatment naive CD with a similar trend in UC, 
compared to controls (Figure 16F). 
 
 
Figure 16 Cxcr5-Cxcl13 immunologic pathway revealed to play an important role in DSS-
induced colitis upon transient ω-6 fat diet. (77) Flow cytometry showed significantly 
decreased number of Cxcr5+ CD4+ T cells in the mesenteric lymph nodes (MLN), but not in 
the spleens (SPL) of ω6-R40 compared to C-P120  (n=3-3 animals, 2 MLNs per mice, 
altogether 6 lymph nodes per group). (C-E) Cxcl13 antibody (ab) treatment protected mice 
against DSS-induced colitis (n=5-5). Arrows indicate intraperitoneal ab treatment. Cxcl13 
ab treated mice had a tendency for decreased weight loss during DSS-challenge. This 
finding was associated with longer colons and decreased histologic severity of colitis in the 
Cxcl13 ab treated group compared to controls. (F) Significantly increased CXCL13 
concentration was measured in serum of treatment naïve human pediatric CD patients, with 
a similar trend in UC.  Error bars represent standard error of the mean (60). *p<0.05, 
**p<0.01, unpaired t test. CD: Crohn’s disease; UC: ulcerative colitis. 
B A C 
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4.3 Clinical results of FMT 
4.3.1 FMT treatment outcomes of CDIF patients  
All 4 CDIF patients without underlying disease (P2, P4, P5 and P9) had resolution 
of their symptoms for more than 2 months following a single FMT.  
Out of the 6 patients with complicating clinical conditions, only 2 (P6 and P8) had 
obvious clinical benefit from C. difficile directed antibiotic therapies prior to FMT.  These 
patients responded well to a single FMT, including the youngest solid organ transplant 
patient receiving FMT to date (on concurrent immunotherapy with tacrolimus and 
mycophenolate mofetil). However, both patients were treated with antibiotics for upper 
respiratory infections within the 2-month follow up period and developed recurrent CDIF. 
Both received repeat intra-gastric FMT with full resolution of their symptoms for over 2 
months. 
The UC patient (P1) required FMT 3 times to clear CDIF, but still had colectomy 
during his subsequent clinical course in spite of being free from C. difficile. Our second 
patient with UC (P10; maintenance mesalamine therapy only) had rapid resolution of her 
symptoms after FMT for 9 weeks, then experienced a C. difficile-positive flare of her UC 
and was started on steroids and 6-mercaptopurine along with oral vancomycin for 2 weeks. 
She responded well to these interventions and subsequently tested negative for C. difficile 2 
weeks after stopping vancomycin. 
There was no obvious clinical benefit from FMT in the CD patient in-spite of 
having a negative C. difficile test 2 months after the treatment. 
One patient (P3) was diagnosed with poorly managed constipation and continued C. 
difficile carriage during her second enema FMT. 
 
4.3.2 Clinical outcomes of patients with ulcerative colitis 
Response and progression of UC patients was monitored by PUCAI during the 
protocol. Clinical remission was defined as PUCAI≤15. Endoscopic disease severity (Mayo 
score) was recorded at the initiation of the trial (colonoscopy) and at the 14-week time 
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point (flexible sigmoidoscopy). Table  contains the PUCAI score and endoscopic Mayo 
score system.  
 
Table 7 Pediatric ulcerative colitis activity index (PUCAI) and endoscopic Mayo score. 
PUCAI Score Endoscopic Mayo Score 
Abdominal pain: 0-10 Normal or inactive colitis: 0 
Rectal bleeding: 0-30 Mild colitis: mild friability, erythema, decrease in vascularity: 1 
Stool consistency: 0-10 Moderate colitis: friability, marked erythema, vascular pattern absent, erosions: 2 
Number of stools per 24 hours: 0-15 Severe colitis: ulcerations and spontaneous bleeding: 3 
Nocturnal stool: 0-10   
Activity level: 0-10   
 
Serial FMT transiently supported immunotherapy withdrawal in pediatric UC 
patients in our small pilot study. The FMT enabled all 3 patients to be symptom-free for at 
least 4 weeks following FMT and supported the withdrawal of immunotherapy (no 
treatment other than mesalamine) for more than 105 days in all. The number of FMT 
treatments significantly correlated with the time of being immunotherapy-free (r=0.998; 
p=0.04). 
Following our promising pilot study, we developed an IND approved phase 1 
clinical trial providing FMT for six patients. Only one patient (P001) remained in the trial 
for the first six months. All others had to be withdrawn from the study according to 
exclusion criteria for worsening symptoms. The single patient (P001) with prolonged 
remission (PUCAI≤15) throughout the course of the study had endoscopic remission at 
enrollment (Mayo 1), and 2 weeks after the last weekly enema (Mayo 0; 14 weeks of the 
trial). However, subjects with pseudopolyps, and/or moderate to severe endoscopic disease 
(5 patients, Mayo 2-3) developed moderate to severe symptoms within 2 days to 8 weeks 
and were withdrawn from the study. The length of clinical remission was negatively 
correlated with mucosal disease activity at the initiation of FMT (r=-0.845, Spearman: 





Figure 17 Mucosal disease activity and therapeutic response to FMT in the phase 1 FMT 
study. The length of clinical remission negatively correlated with mucosal disease activity 
at the initiation of FMT (r=-0.845, two-tailed Spearman: p=0.03). Endoscopic Mayo score 
was arbitrarily increased by 1 if pseudopolyp/s were detected. 
 
Two of the patients withdrawn from the study had colectomy for steroid dependent 
disease within one year from the time of dropout. One patient’s clinical course was 
complicated by cytomegalovirus (CMV), which was diagnosed at the colonoscopy prior to 
the first FMT. Following failure of FMT, she had limited response to ganciclovir, 6-
mercaptopurine (6MP) and infliximab (IFX), entered a phase II adult trial of an 
experimental drug. Currently, she is in clinical remission. One patient had poor weight gain 
on 6MP and low dose intermittent steroids with mild clinical disease activity and has been 
recently advanced to IFX therapy. One geographically distant referral patient was lost to 
follow-up. 
The single patient with positive response to the treatments remained in remission on 
monthly FMT via enema up to 6 months into the protocol. Unfortunately, he was unable to 
receive more treatments secondary to the trial being placed on hold for a serious adverse 
event in another patient (see below). Nevertheless, he remained in clinical remission off of 
any therapy for more than 3 months, with a normal fecal calprotectin (110.9 mcg/g, 
ULN=162.9 mcg/g) at 2 months after the last FMT. Later, he developed bloody diarrhea, 
which responded to weaning steroids and oral mesalamine therapy.  
A summary of all our patients’ treatment can be seen in Table 8. Endoscopic and 





Table 8 The number of days in remission negatively correlated with the initial Mayo score 
of patients enrolled into our pilot trial (P1-3) and phase I study (P001-006). Altogether 178 
FMT were delivered in our center. Patients received various numbers of FMT. Endoscopic 
evaluation (colonoscopy and flexible sigmoidoscopy) with Mayo scoring was completed on 
the first day of the protocol and at 14 weeks (2 weeks after the weekly enemas). Patients in 
remission or with mild disease activity (Mayo score 0-1) stayed in remission and completed 
the 14-week evaluation with Mayo score=0. Patients who had moderate disease activity 
(Mayo score 2-3) or presented with pseudopolyp developed UC symptoms and were 
withdrawn from the study (* and # labels the patients who were enrolled in both the pilot 







Mayo score after 
14-week FMT 
Days spent in 
remission 
P001* 32 (1) 1 0 204 
P002 10 2  10 
P003# 17 (1) 1 (P)  21 
P004 9 2  9 
P005 2 3  2 
P006 24 (5) 1 (P)  58 
P1 30 0 0 261 
P2* 25 1  0 159 








Figure 18 The endoscopic and histological picture of patient colons from this phase 1 (A) 
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4.3.3 Adverse events monitoring 
The risks of FMT in pediatric patients are unknown, but based on the experience in 
adults with bacterial colitis FMT is usually well tolerated and the risks are believed to 
include: possible transmission of a bacterial or viral disease, allergic reaction, worsening of 
CD related symptoms (bleeding, pain, bowel perforation, or rupture, infection/sepsis), and 
possible but unlikely death.  There is one report of a 61 year old male with CD, refractory 
C. difficile colitis and a history of multiple episodes of E. coli bacteremia, who developed 
E. coli bacteremia within 24 hours of FMT.(111) Given the time course it seems likely that 
the FMT contributed to this development of bacteremia; therefore bacteremia is included as 
a potential risk. Adverse events are possible, but uncommon with nasogastric tube use, 
including vomiting and rarely aspiration. The largest systematic review summarized 67 
published studies (overall 844 patients -76.3% with recurrent CDIF and 13.2% with 
IBD).(68) The cure rate was 90.7% in CDIF; and beneficial effects were reported in 78.4% 
of cases with IBD. 7 publications involved pediatric patients.  The following adverse events 
were reported: fever, rectal discomfort, abdominal pain, nausea, bloating and headache.  
During the phase 1 IND study of pediatric ulcerative colitis patients, 101 FMT were 
delivered. Seventeen adverse events occurred ( 
Table  and Table ). Adverse events included: fever, cough, vomiting, runny nose, 
throat ache, nausea, abdominal pain (solicited) and altered laboratory parameters including 
decreased sodium, decreased hemoglobin, increased AST and ALT (unsolicited). The 
probable and possibly related AEs included fever, abdominal pain and decreased sodium 
level. Additional AEs, such as cough, runny nose and throat ache were considered unrelated 
to FMT, and were attributed to a possible upper respiratory infection. Nausea was present 
on the first day in two cases unrelated to FMT, probably secondary to anesthesia.  
During the study, there was one serious adverse event (SAE; Grade 3: fever and 
abdominal pain), which required hospitalization. This SAE was possibly related to the 
treatment. Based on further evaluation with endoscopy, we concluded that the SAE was 
probably induced by the fecal preparation that was received by the patient with severe 
colonic mucosal disease activity. This may have been an allergic response, or non-specific 
transient, self-resolving inflammatory exacerbation leading to fever. Nevertheless, the DRC 




Table 9 The frequency of adverse events during the IND clinical trial with pediatric 
ulcerative colitis patients. 
 Total # Percentage (%) 
Adverse Events 17 100 
Adverse Event Group   
Solicited 13 76.5 
Unsolicited 4 23.5 
Adverse Event Grade   
Grade 1 (mild) 12 70.6 
Grade 2 (moderate) 3 17.6 
Grade 3 (severe) 2 11.8 
Grade 4 (life threatening) 0 0 
Adverse Event Relatedness   
Unrelated 7 41.2 
Unlikely 5 29.4 
Possible 4 23.5 
Probable 1 5.9 
Definite 0 0 
 
Table 10 Category, severity and relativeness of adverse events of patients during the IND 
approved protocol. 




Week 12 Cough Solicited Grade 1 (mild) Unrelated 
Week 12 Running nose Solicited Grade 1 (mild) Unrelated 
Week 12 Throat ache Solicited Grade 1 (mild) Unrelated 
Week 12 Vomit Solicited Grade 1 (mild) Unrelated 
IMT_UC_
P007 
Week 1 Day 6 (Day 6) Fever Solicited Grade 2 (moderate) Unrelated 
IMT_UC_
P009 
Week 2 Day 2 (Day 9) Fever Solicited Grade 1 (mild) Possible 
Week 2 Day 2 (Day 9) Cough Solicited Grade 1 (mild) Unrelated 
Week 2 Day 2 (Day 9) Vomit Solicited Grade 1 (mild) Unrelated 
Week 1 Day 1 (Day 1) Nausea Solicited Grade 1 (mild) Unlikely 
IMT_UC_
P010 
Week 1 Day 1 (Day 1) Nausea Solicited Grade 1 (mild) Unlikely 
IMT_UC_
P011 
Week 1 Day 1 (Day 1) Nausea Solicited Grade 1 (mild) Unlikely 
Week 8 Fever Solicited Grade 2 (moderate) Possible 
Week 8 Fever Solicited Grade 3 (severe) Probably 
Week 8 Decreased sodium  Unsolicited Grade 2 (moderate) Possible 
Week 8 Decreased 
hemoglobin  
Unsolicited Grade 1 (mild) Unlikely 
Week 8 Increased AST  Unsolicited Grade 1 (mild) Unlikely 
Week 8 Increased ALT  Unsolicited Grade 1 (mild) Unlikely 
Week 8 Abdominal pain Solicited Grade 3 (severe) Possible 
 
4.4 Microbial studies of FMT 
Based on encouraging findings of clinical remission and the current literature about 
gut microbiome and its role in intestinal inflammation, we initiated microbial studies on 
stool samples of the same pediatric patients with CDIF and UC during the FMT. This 
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approach is unique in testing FMT as primary (not adjuvant) treatment modality for 
pediatric UC and FMT; and how this treatment influences the gut microbiome by time. 
 
4.4.1 Increased alpha-diversity following FMT in CDIF patients 
We examined the samples of those CDIF patients who did not have underlying 
clinical conditions and uniformly responded well to FMT (P2, P4, P5 and P9). Species 
richness increased significantly (p=0.0025) following FMT in the recipients, even 
surpassing that of the donor (Figure 19A). Bacterial Shannon’s diversity similarly had a 
significant (p=0.0010) increase upon FMT in the pediatric recipients. The diversity was 
beyond that of the donor (Figure 19B). The post FMT group had species richness and 
diversity similar to that of the healthy group.  
 
  
Figure 19 Microbiome responses to FMT. Alpha-diversity showed exponentially increased 
number of observed species (richness, p=0.0025) and diversity (Shannon’s, p=0.0010) 
following FMT. The CDIF post-FMT group had increased richness (left panel) and 
diversity (right panel) similar to those seen in the healthy control groups. Statistical analysis 
revealed no significant difference between the healthy control group and the CDIF post-
FMT group for richness (p=ns) and diversity (p=ns). The CDIF post-FMT group also had 
significantly increased diversity levels when compared to the donor group (p=0.0010). 
 
4.4.2 Taxonomical changes upon FMT in CDIF 
At the taxonomic level, Bacteroidetes increased in abundance following FMT in 
children without disease, as opposed to the IBD patients who did not respond clinically to 
the FMT (Figure 20). Specifically, several OTUs most closely related to the genus 







































































Bacteroides were found to be more abundant in the post FMT group. The OTU most 
closely related to Bacteroides uniformis had the most significant (p=0.0049) increase in 
abundance after FMT treatment. The other significantly increased OTUs post FMT were 
those belonging to the family Lachnospiraceae.  
 
 
Figure 20 Bar-graph of taxonomical changes in CDIF patients prior and after FMT 
compared to the donor microbial composition.  
 
4.4.3 Microbial analyses of UC patients  
Principal coordinate analysis (PCoA) of fecal bacterial community composition data 
generated from 16S rRNA sequencing revealed that UC samples prior to FMT did not 
clearly separate from the donor. However, those did cluster differently from healthy 
pediatric microbiomes (Figure 21). Interestingly, P001 (Figure 21*) separated the farthest 
from the donor in spite of having received FMT from the same donor one year prior to this 





Figure 21 Principal coordinates analysis (PCoA) of (unweighted Unifrac distances of 
bacterial community composition as depicted by 16S rRNA gene sequencing of fecal 
samples upon serial FMT. Prior to FMT, the microbiomes of UC patients separated from 
those of healthy children but did not separate clearly from donor. Surprisingly, patient 
(P001*) who received FMT previously from the same donor shared the least degree of 
similarity with the donor as compared to the other UC patients. 
 
4.4.4 Microbiome shifts upon FMT 
We had the ability to study microbiome responses to intense FMT over a 6-month 
period in one patient only (Figure 22). The fecal microbiome of P001 shifted towards that 
of healthy children. Nevertheless, the patient’s microbiome remained distant from both the 







Figure 22 Fecal microbiome composition in our patient with prolonged remission (P001) 
moved towards both the donor and healthy pediatric microbiomes during the 6 months of 
the FMT series. 
 
4.4.5 Prolonged microbiome effects of serial FMT in two patients  
Two patients participated both in our discovery FMT trial(99) and this study, with 
more than a year separating the two.  Both patients received their FMT series from the 
same donor during an overlapping time period. This provided an unprecedented opportunity 
for us to examine the prolonged effects of an extended course of FMT (series of 25 and 22 
FMT, respectively). Upon serial FMT, these patients experienced normalization of their 
microbiomes, characterized by large shifts toward a state resembling healthy pediatric 
composition (Figure 23, arrows). In contrast, upon suspension of FMT the microbiomes of 





Figure 23 PCoA revealed shift towards the microbiome profiles of healthy children upon 
FMT in patients with long-term follow-up. Within 7 to 10 weeks (P003 and P001, 
respectively) FMT patients clustered close to microbiome of healthy individuals. However, 
the lack of treatment (within 10 to 12 months) resulted in a shift back to original state in 
both patients. 
 
We also examined the prolonged microbiome responses in detail from both of the 
UC patients at the level of the operational taxonomic unit (OTU) level and compared those 
to those which were observed in donor stool (Figure 24). Two weeks after 25 FMTs had 
been administered, 17% of the OTUs detected in P001 at baseline (prior to FMT) remained. 
Meanwhile, 12% of the OTUs detected were from the donor. Surprisingly, 71% of the 
OTUs were novel or unknown origin (i.e. not detected either in the recipient prior to FMT, 
or in the donor). Twelve months after the last FMT, these numbers shifted. Thirty two 
percent (32%) were original patient OTUs (detected prior to FMT treatment), 13% were of 
likely donor origin, and 55% were novel or unknown origin. In addition to shifts in the 
potential origin of OTUs, there were notable changes in OTU level richness with an 
increase observed at 2 weeks, but a decline observed 12 months after the last FMT. Similar 
changes occurred in P003. Two weeks after last FMT in P003, the abundance of OTUs by 
origin was the following: 28% preserved from prior to FMT, 13% originated from donor 




























10 months after last FMT (32%, 10% and 58%, respectively). In the meantime OTU 
richness changes were very similar to those observed in P001 (Figure 24). 
 
	  
Figure 24 Proportions of OTUs by known origin following FMT (left panel). Surprisingly, 
the highest proportion of OTUs observed in both patients observed were of novel or 
unknown origin, arguing for reconstitution of the recipient microbiomes as opposed to 
transplantation of donor bacteria. In the meantime, about 10% of donor bacteria appear to 
engraft in a prolonged fashion in pediatric UC patients following FMT. OTU number 
changes upon serial FMT (right panel). Two weeks following FMT, the OTU numbers 
increased from 177 to 532, and from 338 to 584, respectively. However, cessation of 
treatments resulted a drop in OTU numbers close to the original state (to 252 and 286 OTU, 
respectively). 
 
4.4.6 Remarkable bacterial composition changes in pediatric CDIF after a single 
FMT 
We next focused our attention to bacterial operational taxonomic unit (OTU) 
changes secondary to FMT. OTU richness significantly increased in the CDIF group 
(Figure 25; p=0.0286) 8 weeks after FMT. We compared the OTU changes secondary to 
FMT in CDIF patients to a small cohort of pediatric UC patients who received an intense 
course of FMT (22-30 treatments) over 6-12 weeks from the same universal donor as our 


































Interestingly, there was only a tendency toward increased OTU numbers in UC in 
response to serial FMT (Figure 25). This finding indicated an increased microbiome change 
upon a single FMT in CDIF compared to that from serial FMT in UC. 
We also examined OTU persistence, and donor engraftment in CDIF recipients 
secondary to FMT. We determined OTU persistence in healthy children over 2 months to 
facilitate the interpretation of FMT-induced microbiome variation. Healthy children 
retained an average of 40% of their OTUs between repeated stool collections over an 8-
week period (Figure 25). Compared to healthy children, the OTU profiles of CDIF patients 
retained a highly significantly (Figure 25; p=3.8x10-10) lower proportion of their original 
OTUs following FMT. Remarkably, only 1% of the pre-FMT OTUs were detected 8-9 
weeks after a single stool transplant upon resolution of CDIF. OTU retention was 
significantly lower in CDIF than in the UC patients (Figure 25; 1% vs. 18%; p=0.0024). As 
for donor engraftment, CDIF patient retained 26% donor OTUs at 8-9 weeks, which were 
not detected in their stool prior to FMT.  Donor engraftment after a single FMT was 
significantly higher in the CDIF patients ~2 months after the treatment than in UC patients 
only 2 weeks after a series of FMTs from the same donor (Figure 25; 26% vs. 11%; 
p=0.00015). The proportion of novel (neither present in pre-FMT recipient, nor the donor) 
OTU was remarkably high in both CDIF and UC, but this did not show significant 
difference between the two patient groups (Figure 25; 73% vs. 71%; p=ns).  
There was no correlation between the proportion of preserved OTUs and the age of 
individuals in the CDIF, UC, or control groups. 
 
Figure 25 OTU numbers (richness, left panel) increased post-FMT in rCDIF (recurrent 
CDIF) compared to pre-FMT (p=0.0286). However in UC patients, there was only a 
tendency towards increase in OTUs upon FMT (p=ns). OTU preservation (middle panel) 
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was significantly lower in both rCDIF and UC patients compared to controls (p=3.8x10-10 
and p=1.67x10-5 respectively). rCDIF patients also had significantly lower OTU 
preservation than UC (p=0.0024). Additionally, donor engraftment (26% average) 2 months 
after FMT was significantly higher (p=1.49x10-4) in rCDIF than in 2 weeks after a series of 
FMT in UC (11% average; right panel). In the meantime, there was large number of novel 
OTUs detectable in both rCDIF (73% average) and UC patients (71% average) after FMT, 
which did not differ significantly (p=0.458) between the two groups. 
 
4.4.7 Normalization of microbiome composition (beta-diversity) upon FMT in CDIF 
patients  
Using the same universal donor in 9/10 cases provided a unique opportunity for us 
to examine the microbial changes upon a single fecal transplant. Prior to FMT all CDIF 
patient clustered distantly from the donor and healthy children on PCoA, with the exception 
of one patient with overflow diarrhea and C. difficile carriage. On average the stool 
communities of pre FMT patients shared 9.8% similarity with the universal donor and 6% 
similarity with healthy children, based on unweighted Unifrac distances. Post-FMT, 
patients shared 30% similarity with the healthy children and 31% similarity with the 
universal donor, both of which were significant findings (p=5.37×10-9 and 3.65×10-99, 
respectively). When comparing the other healthy group’s gut microbiome to CDIF patients, 
the two groups were 7.5% similar preFMT and 29.8% similar postFMT (p=4.3×10-36).  
The CDIF patients without any underlying clinical condition responded to FMT 
with major microbiome shifts after 8 weeks.  Recipient microbiomes clustered between 
healthy children and the microbiomes of the single standardized donor following FMT 
(Figure 26). One of these patients (patient 4) was found to be positive for C. difficile 4 
months after FMT during an upper respiratory infection, without gastrointestinal 
complaints. He was considered an asymptomatic carrier. Interestingly, asymptomatic 





Figure 26 Principal Coordinate Analysis (PCoA) revealed a major shift (orange arrow) in 
rCDIF (recurrent CDIF) patient microbiomes upon FMT to a similar composition of 
healthy children and donor samples. Patient 4 (*) was found to be an asymptomatic carrier 
for C. difficile 4 months after FMT. Apparently, this carrier state clustered with recipient 
microbiomes at 2 months after FMT. When compared to UC patients receiving a series of 
FMT, microbiome shifts were greater in rCDIF (orange arrow) than in UC (pink arrow). 
[n=4 rCDIF, 3 UC, 3 individuals in healthy group 1 and 13 healthy group 2] 
 
4.4.8 Microbiome shifts in CDIF following FMT are more pronounced than in UC 
When comparing fecal microbiome responses to FMT, we found a more 
pronounced composition shift in the CDIF patients than in UC (Figure 26). Importantly, 
CDIF patients who received just one FMT treatment had larger shift compared to UC 
patients who received serial FMT.   
 
4.5 MUCOSAL TRANSCRIPTOME AND EPITHELIAL CELL 
PROLIFERATION CHANGES AFTER THE FMT SERIES  
Examined the samples of our pilot study subjects, RNA sequencing demonstrated 
that 742 genes decreased in expression (>1.5 fold decrease in expression, false discovery 
rate [FDR]<0.05) in the rectal mucosa of the patients (n=3) 2 weeks following FMT 
(detailed data not shown). Only 12 genes increased significantly in terms of relative 
expression. Down-regulated genes were compared by gene ontology enrichment analysis to 




FMT (FDR>0.97). Genes linked to leukocyte activation and mitotic cell cycle progression 
were down-regulated. More specifically, 7 biological processes were highly significantly 
(FDR<10-5) enriched by more than 2-fold in association with the down-regulated genes, 
compared to the control genes (Figure 27).  
 
 
Figure 27 Biological processes with more than 2 fold over-representation (FDR <10-5) in 
the down-regulated genes compared to control following serial FMTs in UC patients. 
 
Based on these findings, we decided to functionally assess the consequences of 
FMT in the colonic mucosa of the patients in respect to mitotic activity changes. We found 
that 2 out of the 3 patients showed evidence that epithelial mitoses had been reduced by 






Figure 28 Epithelial Cell Mitosis Suppression Following FMT. In 2 out of 3 patients, the 
numbers of epithelial mitoses (blinded examination of 500 epithelial cells) decreased by 
more than 50% following high intensity FMT. Mitoses were highlighted by histone (H3) 
immunohistochemistry. Magnification 40x 
  



























5.1 Cellulose supplementation early in life ameliorates acute colitis in adult mice 
Murine pediatric cellulose supplementation induces transient trophic, anticolitic and 
microbiome-modifying effects according to our study. The cellulose-stimulated lengthening 
of the colons persisted for 10 days, which was associated with protection against DSS.  
Additionally, we found that the cellulose-dependent trophic and anticolitic effects were 
transient by being lost 40 days after reversal of cellulose supplementation. This later result 
highlights the remarkable capacity for the large bowel towards anatomical reconstitution in 
mammals during young adulthood (between P90 and P120). The means by which DSS 
provokes colitis is still of debate, but recent studies indicate that it induces hyperosmotic 
stress leading to NF-kB activation through the posttranslational methylation of protein 
phosphatase 2A.(112) Regardless, toxin-induced colitis is bound to depend on the toxin-
amount/mucosal-surface-area ratio. Lengthier colons with larger mucosal surface in the 
same species are likely to be less vulnerable to the toxin if the animal consumes the same 
amount. The average surface area increase induced by cellulose supplementation in this 
dietary model was calculated to be around 30%. Consequently, our study suggests that 
cellulose supplementation during animal development induces growth of the large intestine, 
thereby leading to an increased mucosal surface that decreases the toxin to surface-area 
ratio and ultimately provides protection against noxious insults.  
Dietary fibers have been shown to modify both microbial composition and colitis 
susceptibility in mammals. Therefore, we studied the consequences of dietary cellulose on 
the colonic mucosal microbiome composition as well. Cellulose supplementation induced a 
significant microbiome separation by PCoA. Cluster differences were less pronounced 
following 10 days of reversal to low cellulose, but those were not diminished completely. 
This observation was true for the increased richness of the microbiome during high 
cellulose supplementation and 10 days of reversal as well. These findings support the 
presumption of De Filippo and colleagues (37) that increased dietary fiber consumption 
may be an important reason for the enhanced stool microbiome richness in rural African 
children compared to European children. Given that the animals in this work were 
maintained in the same facility room and even transferred between cages, our results also 
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indicate that cellulose supplementation dynamically increases the inter-species tolerance 
within mammalian commensal microbiota thereby inducing increased gut microbial 
richness within the same geographic environment. This finding contradicts the conclusions 
of De Filippo and colleagues (37), who suggested that a fiber-rich diet provides means to 
maintain overall enteral bacterial species richness by sustaining a diverse microbial 
environment within a geographical location. Rather, cellulose consumption (i.e. fiber-rich 
diet) can increase intestinal microbiota richness within the same microbial environment and 
can readily support mucosal protection. 
At the phylum level, Actinobacteria decreased persistently during high cellulose 
supplementation and following 10 days reversal. This finding coincides with observations 
in TLR2-/- mice, which can be more susceptible to colitis than WT.(101) Actinobacteria 
were present in greater abundance in colonic mucosa of TLR2-/- mice similar to human 
studies on IBD associated microbiome.(56; 113)  The decreased abundance of 
Actinobacteria in our current work was associated with a milder form of DSS colitis, 
supporting a potential colitic effect for this phylum in mammals.  
Three families were modified in a prolonged fashion (in both HC and HCR10) upon 
cellulose supplementation: Coriobacteriaceae (a family within the phylum Actinobacteria) 
decreased, and Peptostreptococcaceae and Clostridiaceae increased compared to controls. 
The abundance of Peptostreptococcaceae and Clostridiaceae increased in human studies 
examining biopsies and stool samples from chronic pouchitis patients.(114; 115) Intestinal 
mucosal ulceration and the severity of chronic pouchitis were associated with increased 
numbers of different species within Peptostreptococcaceae and Clostridiaceae. Based on 
these findings, it is difficult to interpret the significance of the changes affecting these taxa 
in our experiments where pre-inflammation (no DSS exposure) microbiome composition 
was examined. Similar debates about microbiome associations of IBD (i.e. primary change, 
or secondary effect of inflammation) have been raised.(116) 
The overall decline of family level composition variation upon 10-day reversal from 
high cellulose diet may indicate that the persisting gut morphological changes (i.e. longer 
colons with larger mucosal surface) may be more important towards colitis protection than 
the remaining shifts in community composition of the colon in this feeding model. This 
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conclusion is supported by a recent publication highlighting the importance of Allobaculum 
(a member of the Erysipelotrichaceae) and Paludibacter (a member of the 
Porphyromonadaceae) as key contributors to DSS colitis sensitivity.(117) We detected 
reduced abundances of Erysipelotrichaceae and Porphyromonadaceae on high cellulose diet 
(Figure 6), which could contribute to colitis protection (with less severe colitis). However, 
most of these changes diminished after 10 days reversal (both in our discovery and 
validation experiments) suggesting a less important influence of the microbiome on the 
colitis of the HCR10 mice than their longer large intestinal phenotype. 
 
5.2 Loss of omega-6 fatty acid induced pediatric obesity protects against acute 
murine colitis 
Western diets (usually containing high fat, especially ω-6 fatty acid) have been 
proposed to increase the risk of IBDs.(35) Dietary ω-6, and its metabolites have been 
shown to have pro-inflammatory properties and to exaggerate immunological responses in 
animal models.(118) The increased intake of essential ω-6 fatty acid, such as linoleic acid, 
has been associated with ulcerative colitis in a prospective human trial.(46) These findings 
are supported in studies on rodent models of colitis.(119) In the meantime, the effects of 
transient pediatric exposure to high ω-6 fatty acid on successive colitis susceptibility have 
not been examined. Early adulthood is the peak for IBD presentation, which indicates the 
potential importance of pediatric dietary exposures (including increased ω-6 consumption) 
in the developmental origins of the diseases. In this study, we examined how ω-6 induced 
transient obesity during pediatric development may impact colitis in young adult mice. On 
the contrary to our expectations, we found that reversal from ω-6 induced pediatric obesity 
protected mice from acute colitis in young adulthood. The colitis protection was exclusive 
to the acute/chemical injury model, since chronic colitis severity was not modulated by the 
same dietary intervention in both IL-10-/- mice,(109) and in the adoptive transfer model of 
CD4+, CD45RBhi+ T cells into Rag1-/- mice.(110)  
The acute colitis protection was specific to ω-6 (corn oil), at least in comparison 
with saturated fat (milk fat). This finding is consistent with recent work showing that 
saturated fatty acids (such as palm oil, which is similar to milk fat in fatty acid 
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composition) augmented small intestinal inflammation in a CD relevant murine model 
independently of obesity.(120) Additionally, Devkota, et al. found that saturated fat, but not 
polyunsaturated fat, triggers colitis in genetically susceptible mice in association with the 
bloom of Bilophila wadsworthia.(121) Indeed, clinical studies indicate that the type of 
dietary fat consumed rather than obesity itself is risk factor for the development of IBD.(35; 
122; 123) However, with the experiments in this work, it cannot be ruled out that other 
immunomodulator substances both in corn oil, or milk fat may have played a role in the 
observed phenotype modifications.  It is important to highlight that the phenotype observed 
in our work was also dependent on the cessation of increased ω-6 consumption, since obese 
mice during high ω-6 feeding were not protected from DDS induced colonic inflammation.  
Importantly, the velocity and extent of weight loss was similar in both the ω-6 and milk-fat 
reversal groups. Therefore, the colitis protection by transient ω-6 supplementation cannot 
be explained simply on the basis of weight loss. Rather, ω-6 supplementation during 
mammalian pediatric development appears to specifically induce a less colitis prone 
microbiome and host immunophenotype in a prolonged fashion.  
Genetic work indicates that the development of IBD can be influenced by diverse 
[over 163 susceptibility loci (124)], potentially interactive genetic polymorphisms,(125) 
each of which contribute to the diseases with low penetrance. Monozygotic twin and other 
epidemiologic studies underscore the involvement of primarily non-genetically modulated, 
environmentally responsive, intercalating biologic systems.(48) The disease specific 
disruption of a single biological system, such as the microbiome, appears to be relatively 
limited in IBD,(56; 126) in agreement with the genetic observations. Rather, the 
individually small, but interactive dysregulation of multiple biologic systems within the 
host-microbiome network (127) may lead to the onset of IBD. Therefore, if one wishes to 
explore the consequences of a potentially critical environmental change in respect to IBD 
development, then a parallel multi-omic approach is warranted.(30) We set out to examine 
metagenomic, colonic mucosal and immunologic associations of transient ω-6 feeding 
induced acute colitis protection.  Importantly, the colitis protection could be transmitted by 
the fecal microbiome into germ free mice underscoring the participation of the microbiome 
in the dietary intervention induced phenotype. The different genetic background of 
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germfree recipients in comparison to the donor mice (used in all the other experiments) 
highlights the translational relevance of the microbiome findings by overarching the 
boundaries of single mouse strains. Enterococcus was specifically decreased in the colonic 
mucosal microbiome of the ω6-R40 group (Figure 2E). Recently Enterococcus has been 
shown to trigger colonic inflammation in mouse model experiments.(128; 129) 
Additionally, increased abundance of Enterococcus was found in patients with ulcerative 
colitis, and it correlated with disease activity and severity.(130) These observations support 
the potential importance of the ω-6 fat reversal induced decrease of mucosal Enterococcus 
to participate in colitis protection.  
In respect to the colonic mucosa, we did not detect significant epigenetic (DNA 
methylation) and transcriptional changes associated with the examined dietary intervention. 
However, a trend for decreased mucosal Cxcr5 expression was found in the reversed 
animals. Count to threshold values for Cxcr5 were very low suggesting that the signal may 
have been originated from mucosa associated leukocytes derived from mesenteric lymph 
nodes (MLN) rather than from epithelial cells [which generally comprise >90% of the cell 
population in the colonic mucosal scrapings (131)]. Multi-parameter flow cytometric 
analysis of T cell subsets revealed a significant reduction of Cxcr5+ CD4+ T cells in the 
MLN of the high ω-6 reversed animals. Cxcr5 and its ligand B-lymphocyte chemo-
attractant (or Cxcl13) has been shown to orchestrate lymphoid organogenesis and the 
migration of CD4+ T cells from the mantle zone to the more central regions in lymphoid 
follicles. The expression of Cxcr5 on CD4+ T cells is induced by the interaction of OX40 
(or CD134) and its ligand OX40L, thereby serving as an upstream event for the Cxcr5 
dependent T cell migration.(132; 133) Constitutive OX40/OX40L interaction stimulates 
autoimmune-like diseases, such as interstitial pneumonia and spontaneous colitis.(134) 
Inhibition of the OX40/OX40L interaction and secondary Cxcr5 expression in CD4+ T 
cells decreased the severity of DSS-induced colitis in mice.(135) CXCR5+, IL-21 
producing CD4+ T lymphocytes have been shown to play an important role in IBD.(136) 
All these publications indicated that CXCR5-CXCL13 pathway may play in an important 
role in controlling mammalian intestinal inflammation. Therefore, we examined the effects 
of anti-Cxcl13 (the ligand of Cxcr5) immunotherapy in modulating DSS colitis. Anti-
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Cxcl13 treatment was protective. Consequently, we examined CXCL13 levels in treatment 
naïve IBD patients. The plasma concentration of CXCL13 was significantly elevated in 
children at the diagnosis of CD with a similar trend in UC, compared to controls. This 
result was consistent with our prediction that the CXCL13-CXCR5 pathway may be 
important in the pathology of IBD. The observed elevation of serum chemokines was not 
mirrored by gene expression changes at the intestinal mucosal level. Our recent work with 
treatment naïve pediatric UC colon biopsy samples,(137) and the observations of others in 
untreated ileal mucosal samples of pediatric IBD patients (127) has not detected differences 
in CXCR5, or CXCL13 expression compared to controls. These results coincide with our 
findings in the murine model system of the present work, indicating that the CXCL13-
CXCR5 pathway is more relevant for leukocyte than epithelial signaling in respect to IBD 
development. The lack of colitis protection in the chronic murine models suggests that this 
specific chemokine signaling is more important in modulating the onset and flares of 
disease rather than the maintenance of chronic inflammation in IBD. 
Chemokines have been recognized as novel therapeutic targets for IBD, but 
CXCL13 specifically was not implicated.(138) Our results may set the stage for developing 
CXCL13 directed biologic treatments for the disease group in the future. Interestingly, 
tofacitinib is an emerging Janus kinase inhibitor utilized in IBD therapy,(139) which has 
been observed to suppress CXCL13 concentration in synovia of rheumatoid arthritis 
patients. This finding supports our predicament that the CXCR5-CXCL13 pathway may be 
a target for future biologic treatments in IBD.(140)   
 
5.3 The manipulation of microbiota as a possible therapeutic option in pediatric 
gastrointestinal disorders 
Similarly to others, we found FMT to be safe and highly effective for the treatment 
of pediatric recurrent CDIF in patients without complicating clinical conditions. According 
to the microbial data, we found robust switch in CDIF patients’ microbiome following 
FMT.  
As the ulcerative colitis study, our results indicate that FMT is safer and more 
effective in patients who start the treatments with endoscopic remission (endoscopic Mayo 
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score 0-1 without pseudopolyps). Indeed, if we included our inception cohort results (99) 
when examining the relationship between mucosal disease status and response to FMT 
during withdrawal of immunotherapy, we found an even more significant correlation 
between endoscopic disease activity at treatment initiation and clinical remission in 
pediatric UC patients (r=-0.878, two-tailed Spearman: p=0.003; Figure 29).  
 
 
Figure 29 The length of clinical remission negatively correlated with mucosal disease 
activity at the initiation of FMT (r=-0.878, two-tailed Spearman: p=0.003).  
 
We hypothesize that this may be related to an inhibition of the dynamic interaction 
between the gut microbiome and the colonic mucosa during active disease. Such inhibition 
would limit the success of microbiome based therapeutic interventions in UC during 
disease flares secondary to host unresponsiveness. Indeed, gene expression and gut 
microbiome associations have been shown to be decreased in clinically active UC patients 
compared to controls.(56)  
Our phase I withdrawal study is unique in many ways compared to prior trials 
investigating FMT in UC: 
1. Our protocol is the only immunotherapy withdrawal study of FMT in UC to 
date. This characteristic created a strong internal control for therapeutic efficacy 
of FMT within each patient compared to prednisone treatment.  
2. All of our patients were children or young adults without any co-morbidity, 




3. The majority of our patients had short disease duration (3-43 months) prior to 
FMT, which according to Moayyedi et al.(82) may have led to an increase in 
FMT efficiency. 
4. 83% (5 out 6) of the recipients received stool from a single donor, limiting 
biologic variation on the donor side. 
5. The intensity of FMT therapy was considerably higher than other FMT trials to 
date. 
 
Overall, fecal transplantation was generally well tolerated and safe. The one SAE of 
fever leading to hospitalization is an event that has been recognized in adult IBD patients 
receiving FMT and has been observed to be self-resolving in the majority of the cases.(78) 
Our clinical impression is that worsening disease during the course of FMT is likely to be a 
sign for treatment failure, and cessation of therapy should be seriously considered in such 
instances. 
Correlative metagenomic studies showed shifts in our pediatric UC patients towards 
healthy pediatric microbiome composition with FMT. However, cessation of FMT resulted 
in return to the original composition along with disease recurrence in those who transiently 
benefitted from our treatment protocol. Interestingly, the microbiome of the single patient 
with therapeutic success in this study separated the farthest from the donor. This 
observation is in agreement with the publication by Suskind et al.(141) in which they 
observed the highest clinical benefit from FMT in pediatric CD patients where they used 
donors with the most distant microbiome composition form the recipient. 
In conclusion, our findings underscore the importance of mucosal disease staging 
prior to considering FMT as a primary treatment modality for UC. While our patients 
PUCAI score placed them in the “mild” range, the endoscopic staging did not agree, further 
emphasizing importance of relying on mucosal disease staging and not just subjective 
measurements like PUCAI. Patients with medically induced mucosal healing, or mild 
endoscopic disease may benefit the most from FMT. Additionally, pretreatment 
microbiome analysis could identify the most ideal donor candidates from a preferentially 
existing donor pool, based on microbiome composition distance from the recipient. Our 
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observations further the notion that donor stool with the most distant microbiome 
composition form the recipient may provide the most optimal outcome during IBD directed 






1. There is a direct link between nutrition, microbiome and host response.  
 
2. Postnatal exposure to different nutrients (such as cellulose or fat) has transient or 
persistent effect on intestinal homeostasis and predispose to the development for 
intestinal inflammation. 
Even temporary microbial and intestinal changes following cellulose and high ω-6 
supplementation were linked to transient protection against DSS induced colitis in 
mice. 
 
3. Complex bacteriotherapy, such as FMT provides treatment and/or the resolution of 
symptoms for patients suffering in CDIF and IBD via microbiome alteration.  
We established an FMT protocol to provide treatment for pediatric patients with 
CDIF and UC. The complex microbial changes were associated with the resolution 




To better understand the fascinating association of nutrition, intestinal microbiota 
and host response, I examined the complexity of microbial responses altered by nutrition in 
mouse models. This work includes the first in depth analysis of effects of dietary cellulose 
supplementation on the composition of the mammalian colonic mucosal microbiome. The 
results indicate a transient effect of this nutritional intervention even following a prolonged 
high cellulose exposure. The developmental origins-based nutritional approach (testing the 
prolonged effects of a temporary nutritional exposure during the pediatric period) 
demonstrated that the colonic trophic effects of cellulose are also transient.  These findings 
underscore the significant constitutional and morphological adaptive capacity of the colonic 
microbiome and the large intestine, respectively. Temporary microbial and intestinal 
changes were associated with transient protection against experimental colitis in mice. Such 
massive adaptive capabilities demonstrate the dynamic responsiveness of the mammalian 
gut towards luminal physical/compositional changes. Furthermore, transient high ω-6 diet 
during pediatric development in mice induced prolonged protection against murine colitis, 
which associated with persistent colonic mucosal microbiome and lymphoid organ 
composition changes.  
This novel nutrition-microbiota-host paradigm fits with the well-known clinical 
observation that the modulation of microbiome by complex fecal microbiota transplantation 
(FMT) treats antibiotic-resistant Clostridium difficile infection (CDIF) and associated with 
the improvement of inflammatory bowel disease (IBD) symptoms. Our bench-side research 
developed into a bedside clinical trial, by providing FMT for pediatric patients with 
recurrent CDIF and ulcerative colitis (UC). Overall, FMT was generally well tolerated and 
safe. The complex microbial changes were associated with the resolution of GI symptoms 
in our patient cohort. 
These findings may bare important implications for the nutritional developmental 
origins of IBD and promote the future development of novel preventive and therapeutic 





A gyermekkorban végbemenő külső behatások hosszantartó változásokat hoznak 
létre a szervezetben, melyek később betegségek kialakulásához vagy éppen ellenkezőleg, 
betegségekkel szemben védelmet jelenthetnek. Ez a kritikus időszak gyermekkorban 
különösen jelentős figyelmet érdemel. A különböző táplálkozási hatások megváltoztatva a 
mikrobiomot a gyulladásos betegségek kialakulását/lefolyását befolyásolhatják. A 
táplálkozás-microbiom-host interakció szélesebb körű megértéséhez egér modellben 
vizsgáltuk különböző táplálkozási tényezők (cellulóz és ω-6 zsírsav) és azok hatását a 
mikrobiomra, illetve ezen valtozások hatását a később kialakuló intesztinális gyulladásra. 
Tézisemben a gyermekgyógyászatban előforduló gasztrointesztinális 
megbetegedésekkel foglalkozom. Ebben a fejlődési időszakban a táplálkozási hatások 
fontos szerepet játszanak a microbiom megváltozásában és ez később gyulladásos 
bélbetegséghez vezethet, illetve a microbiom direkt megváltoztatásával a betegség 
megelőzhetővé válhat. 
Állatkísérleteink eredményeinek függvényében lehetőségünk nyílt, hogy mikrobiom 
vizsgálatainkat kiterjesszük egy újszerű klinikai terápia alkalmazására. Klinikai 
vizsgálataink során komplex mikrobióta széklettranszplantációt (FMT) biztosítottunk 
Clostridium difficile fertőzésben (CDIF) és colitis ulcerosában (UC) szenvedő gyerekeknek. 
A dolgozatomban az FMT komplex hatását vizsgálom a mikrobiomra és a 
gasztointesztinális megbetegedésekre.  
Az eredményeink és további vizsgálatok lehetővé teszik a táplálkozási tényezők 
komplex hatásának szélesebbkörű megértését, az FMT hatását a szervezetre és lehetőséget 
nyújthatnak további mikrobiológiai terápiák kialakításában korai gyermekkorban. A 
táplálkozási szokások megváltoztatása, illetve a mikrobiom direkt változtatása (FMT) a 
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